Human malarial disease: a consequence of inflammatory cytokine release

Ian A Clark*1, Alison C Budd1, Lisa M Alleva1 and William B Cowden2

Address: 1School of Biochemistry and Molecular Biology, Australian National University, Canberra, ACT 0200, Australia and 2John Curtin School of Medical Research, Australian National University, Canberra, ACT 0200, Australia

Email: Ian A Clark* - ian.clark@anu.edu.au; Alison C Budd - alison.budd@anu.edu.au; Lisa M Alleva - lisa.alleva@anu.edu.au; William B Cowden - william.cowden@anu.edu.au

* Corresponding author

Abstract

Malaria causes an acute systemic human disease that bears many similarities, both clinically and mechanistically, to those caused by bacteria, rickettsia, and viruses. Over the past few decades, a literature has emerged that argues for most of the pathology seen in all of these infectious diseases being explained by activation of the inflammatory system, with the balance between the pro and anti-inflammatory cytokines being tipped towards the onset of systemic inflammation. Although not often expressed in energy terms, there is, when reduced to biochemical essentials, wide agreement that infection with falciparum malaria is often fatal because mitochondria are unable to generate enough ATP to maintain normal cellular function. Most, however, would contend that this largely occurs because sequestered parasitized red cells prevent sufficient oxygen getting to where it is needed. This review considers the evidence that an equally or more important way ATP deficiency arises in malaria, as well as these other infectious diseases, is an inability of mitochondria, through the effects of inflammatory cytokines on their function, to utilise available oxygen. This activity of these cytokines, plus their capacity to control the pathways through which oxygen supply to mitochondria are restricted (particularly through directing sequestration and driving anaemia), combine to make falciparum malaria primarily an inflammatory cytokine-driven disease.

Background

The mechanism of the disease caused by Plasmodium falciparum, arguably the pathogen that causes the most human suffering, has been hotly debated for many decades. Clearly, rational adjunct therapy depends on getting this right. For over twenty years the central debate has come from two apparently opposing camps. One champions the mechanical hypothesis, based on the concept of insufficient oxygen reaching vital organs, and the other the cytokine hypothesis, in which excessive release of pro-inflammatory cytokines are the primary driving force of disease and death. The former concept stresses the uniqueness of the pathophysiology of falciparum malaria compared to that of other severe systemic infectious diseases, whereas the latter sees malaria as having fundamentally the same basis as these other conditions, with the adhesive property of parasitized erythrocytes giving it no more than a distinctive flavour.

Critical analysis of the mechanism of falciparum malarial disease would not have been possible without the seminal work of Peter Mitchell [1,2], who identified mitochondria as the ATP-generating powerhouse of aerobic cells, and thus of all aerobic organisms. Among the doors this
opened was the opportunity to understand severe infectious disease by seeing it through the perspective of these organelles. This review largely discusses the relative contribution to disease processes of mitochondria being prevented from getting enough oxygen, and being able to use all the oxygen that reaches them, and the combined effects of these two influences. This includes blood flow restriction in microvessels by parasitized red cells that adhere to endothelial walls (sequestration), the potential restriction to oxygen supply that is unique to falciparum malaria. As discussed below, the broader literature is consistent with the view that sequestration during severe disease is not a passive event that is simply an amplification of what occurs early in infection and in tolerant individuals, but one in which location and avidity of adherence, and, therefore, pathogenic effects, are controlled by inflammatory cytokines.

Despite advances in understanding diseases clinically very similar to falciparum malaria in terms of inflammatory cytokines, enthusiasm for the mechanical obstruction hypothesis seems at least as strong as ever [3-5]. Although much literature now demonstrates dependence of the mechanisms of poor oxygen delivery on excess inflammatory cytokine release, even the most recent members of the vaso-occlusion school [5] still see the cytokine theory of disease as an alternative to be argued against rather than as an essential component of their own disease model. Hence it is timely to bring together an update of the evidence why cytokines are regarded as so central to this disease. In particular, it seems warranted to summarize how broadly the harmful influences of the inflammatory cytokines are now known to extend. By introducing concepts in infectious disease in general, and then moving to the particular case of falciparum malaria, this review expands on these functionally interconnected consequences of excess production of inflammatory cytokines.

Systemic infectious diseases and inflammatory cytokines

There is now remarkably widespread acceptance that cytokines such as TNF and interleukin-1 (see "cytokine storm" in Google) are the essential mechanism of systemic disease caused by infectious agents. Indeed, one would be hard pressed to find an alternative explanation now current for the anorexia, tiredness, aching joints and muscles, fever and sleepiness that patients experience in any systemic infection, including both vivax and falciparum malaria. Neither is it disputed that exacerbated release of these same mediators is the best current line of investigation for the mechanism of severe and life-threatening illness, such as sepsis [6] and influenza [7]. The difficulty, confined to falciparum malaria, is to get its broad acceptance in a research community that has traditionally seen its disease as unique, mechanistically separated from other infectious conditions by the presence of sequestered parasitized red cells often seen in certain intravascular locations at autopsy. To some researchers sequestered parasites are still necessary and sufficient for illness from falciparum malaria to occur, and to cause mortality [4,8]. Much of this section will include parallels between malaria and similar diseases caused by other pathogens, and basic research done on the effects of inflammatory cytokines on normal cells. It also recounts, for the present-day audience, the malarial origin of this concept of disease pathogenesis.

**Intra-erythrocytic death of haemoprotozoa, the original link of TNF to disease**

Nearly thirty years ago, ignorance of accepted malaria wisdom, in a London tumour/virology lab where this attribute was universal, allowed a novel tumour-oriented interpretation to be put on the observation that the non-lethal mouse parasite, *Babesia microti*, was killed by the immune system in circulating red cells [9]. This also happened in some species of malaria parasites with which it cross-protected. Encouragement that this phenomenon was worth pursuing came from the Guy’s Hospital group, then at the top of the malarial immunity tree, who observed the same unexpected and puzzling phenomenon when they challenged malaria-immunized rhesus monkeys [10].

Of particular concern for the then official Guy’s dogma (malarial immunity operates through a specific antibody focussed on the merozoite surface, adopted unquestioned by other major vaccine groups), even unrelated parasites died *en masse* inside red cells when previously immunized monkeys were challenged [11]. In their view this could offer an explanation of why some monkeys had high levels of antibody expected to be protective, yet failed to resist a challenge infection [11], while others with little or no anti-merozoite antibody were immune [12]. A report from the US told a similar tale [13]. Clearly, some powerful influence beyond specific antibody, and inconvenient for mainstream thinking on immunity and vaccine development, was reproducibly occurring.

**Tumour necrosis factor (TNF), the prototype inflammatory cytokine**

The observation that pre-treatment with the Bacillus Calmette-Guérín (BCG) strain of *Mycobacterium tuberculosis* controlled a subsequent infection with any of several strains of babesia or malaria in mice (no antibody, parasites dying in red cells, not phagocytes) was fortuitously timed with the publication of the first paper on TNF [14]. This allowed us, in collaboration with these New York tumour researchers, to propose novel roles for TNF in immunity and disease pathogenesis in malaria and sepsis [15,16]. In summary, through linking the protective
capacity of agents such as BCG with the degree to which they sensitised to bacterial lipopolysaccharide (LPS) it came to be realised that the pathology of LPS toxicity (and subsequently that of rTNF) and Plasmodium vinckei infections in mice were largely identical, cytokine-mediated, events. As noted in a contribution to Brian Maegraith's 1988 Festschrift Proceedings [17], the cytokine approach gave teeth to his inflammation-based arguments on malaria disease of forty years earlier [18].

As reviewed in 1987 [19], this experience with mouse babesiosis and malaria provided the insight that this anti-tumour mediator arguably had roles in both cell-mediated immunity (CMI) and the pathogenesis of infectious disease in general. As well as malaria, this concept was reasoned in 1981 to explain the mechanism of typhoid [15], sepsis in general [16], and viral diseases in 1989 [20], and it eventually spread across all acute infectious diseases (see [21] for a recent review). For example, within a few years it began to dominate the sepsis literature [22,23], and the virulence of different strains of influenza, a disease that is a standard clinical misdiagnosis for imported malaria, has now been expressed in terms of their capacity to induce TNF [24]. While still engendering strong opposition from some malaria researchers [4,25], these ideas have been readily accepted by scientists working on bacterial, rickettsial or viral diseases. A broad literature across infectious disease now describes inflammatory cytokines as having a beneficial role in host defence, but being harmful to the host if produced excessively. Indeed, the acceptance and applicability of this concept is now general enough for its biological evolution to be an independent subject for research [26].

Once neutralizing anti-TNF antibodies became available for human use, they were tested by others for efficacy against malarial parasites and disease. Unfortunately a central tenet of the concept (that the pro-inflammatory cytokines that cause disease are the same mediators that, in lower concentrations, are responsible for the innate immunity that controls parasite growth – see also tuberculosis etc. in next paragraph) was not adequately considered. TNF has been shown to inhibit a mouse malaria parasite in vivo [27], and Plasmodium falciparum in vitro, provided white cells to generate the next downstream mediator, possibly nitric oxide [28], were present [29]. This is consistent with findings in human subjects [30]. Thus it is not surprising that anti-TNF antibody, by removing inhibitory pressure from the pathogen, can enhance the disease in falciparum malaria [31], as shown five years earlier in human sepsis [32].

The broad relevance of these malaria-origin concepts in immunity and disease is best illustrated by noting the consequence of passive vaccination against TNF for Crohn's disease and rheumatoid arthritis, now a large-scale routine treatment [33]. Its practical success puts the relevance of these pro-inflammatory cytokines in human inflammatory disease beyond doubt, and the major side effect (pre-existing or acquired tuberculosis, salmonellosis, or listeriosis becoming fulminant) nicely demonstrates its relevance to CMI against many pathogens. It is unlikely to be coincidental that all three that flare are on our list of organisms that protected against haemoproteozoa parasites, causing intra-erythrocytic death, and priming mice for TNF production [34,35]. Evidently the host was setting up a cell-mediated response that would protect against these organisms. Being non-specific in nature, it also protected against haemoproteozoa as well. From this reasoning Coxiella burnetii, a crude extract of which was an extremely good protectant [36], and primer for TNF (E. Carswell, pers. comm.) will also predictably flare if anti-TNF is given, long term, to an arthritis patient harbouring this human pathogen.

The inflammatory cytokines as a group
In this text, TNF is used as a term of convenience to designate the pro-inflammatory cytokines as a whole. Other cytokines, such as lymphotoxin (LT), interleukin-1 (IL-1), interleukin-6 (IL-6) and soluble Fas ligand (FasL) serve similar functions. In passing, it warrants noting that the term TNF-alpha, while still common, has been obsolete ever since LT ceased being referred to as TNF-beta and reverted to its original name, allowing TNF to do the same. Although the literature connecting the pro-inflammatory cytokines other than TNF to malaria [37-40] is as yet much smaller than that for TNF, this does not imply that their potential for understanding this disease is correspondingly minute. A TNF superfamily of 19 members signalling through 29 receptors has more recently been described [41]. Many of these mediators induce other cytokines and enzymes that add to the inflammatory cascade. For example, TNF induces migration inhibitory factor (MIF) [42,43], and TNF, IL-1 beta and LT generate the inducible form of nitric oxide synthase iNOS [44]. Anti-inflammatory cytokines such as IL-10, IL-4, and transforming growth factor-beta (TGF-beta), also play active roles, and an imbalance between these and their pro-inflammatory counterparts often determines outcome in disease. Some tens of thousands of publications on inflammatory cytokines and systemic inflammatory and other disease now exist.

The pro-inflammatory cytokines most closely investigated in malaria, such as TNF, usually act as homeostatic agents, but can cause pathology if produced excessively. A recently defined example is MIF (see above paragraph), belonging to an ancient gene family, with structural homologues in bacterial organisms. As an indication of the broad relevance and complexity of these cytokines and
their interactions, MIF is also induced in mammals by *E. coli* lipopolysaccharide [42], staphylococcus toxic shock toxin, and streptococcal pyrogenic toxin A [45]. Whether this is direct, or via the TNF they induce, appears not to have been ascertained. Likewise, MIF can act directly, through TNF, or in synergy with it, in generating anaemia, as discussed below. It is, as noted above, TNF-induced, and remarkable for several reasons, one being that its description 40 years ago [46,47], began the concept of what are now called cytokines. Ten years later, and long before MIF was realised to have functions other than migration inhibition and pathogenicity in sepsis (which its inhibition suppresses, in a realistic model, most impressively [48]), it was the first cytokine described in a malaria infection [49]. A few years after its rediscovery as a homeostatic glucocorticoid antagonist [50,51], it has become central to understanding malarial anaemia, as discussed below. It is also increased in malarial placentas [52].

Cytokines such as TNF and IL-1, both increased in a wide range of systemic inflammatory diseases, including falciparum malaria, can induce a late-onset, but long-acting wave of a cytokine termed the high mobility group box 1 (HMGB1) protein, which prolongs and amplifies inflammation [53,54]. This molecule, previously known for several physiological functions, now shows great promise as a therapeutic target in sepsis, in that countering it after the onset of illness has been reported to protect well in experimental sepsis [55,56]. HMGB1 has been shown to be increased, in proportion to degree of illness, in serum from African children infected with falciparum malaria [57]. Like TNF, HMGB1 has roles in other inflammatory diseases [58], reaffirming malaria’s position within their ranks. The malarial context of HMGB1 is reviewed more fully elsewhere [21].

**TNF, a tool to determine the nature of malarial toxin**

The idea of malarial disease being caused by parasites releasing a toxin is even more venerable than that of vaso-occlusion, since it is based on a report by Golgi in 1886 [59], in which he noted onset of fever and rigors at a predictable short interval after the regular shower of new parasites escape from bursting red cells. These principles were much discussed in the first decade of the 20th century [60]. Clearly, something like this was needed to explain how tissue not invaded by the parasite was nevertheless damaged during falciparum malaria. Examples are sites such as the adult kidney and lung, where dysfunction can be catastrophic, yet sequestration never obvious, and often absent. The toxin idea lay fallow for many decades, not helped, in hindsight, by the underlying assumption that toxicity arose directly from a parasite product, in the manner of tetanus toxin.

The proposal that malarial products were not harmful in themselves, but only through causing the infected host to harm itself through generating toxic amounts of molecules that, in lower concentrations, inhibit growth of malarial parasites, gave the toxin concept new impetus [15,16,19]. These papers predicted that the nature of the malarial product that triggers illness could be defined through its ability to induce release of TNF from mammalian cells. A group in London did much work along these lines in the late 1980s and early 1990s [61,62], and concluded it was closely related to phosphotidylinositol (PI) [63]. Others extended this argument to the glycosylated form of this molecule (GPI) [64]. The original proposal that malarial toxin operates through inducing generation of TNF and related cytokines was greatly strengthened when immunizing mice against GPI and then infecting them with one of the mouse malaria parasites protected against certain pathology that TNF causes on injection [65]. Indeed, this study reports having established that GPI appears sufficient and necessary for the induction by malarial parasites of host pro-inflammatory responses *in vitro*. The field has been well reviewed recently [66], with these authors and others expressing doubts about the wisdom of vaccinating against GPI to prevent malarial disease [21,66,67]. As noted some years ago, the need for sufficient TNF to allow immune activation to proceed normally during infections is plausibly why this potentially lethal mediator has survived 300–500 million years of evolution [68]. However, despite recent reaffirmation of the GPI/cytokine/disease concept [69], the group that first suggested that GPI was the main TNF inducer in malaria appear to have recently [25] changed their disease model to one that eliminates a requirement for inflammatory cytokines. In view of GPI having been identified through its capacity to induce pro-inflammatory cytokines, it would have been remarkable to chance upon a molecule that induces these mediators, yet mimicks their actions in their absence. Clarification awaits a more detailed report.

**Breadth, and acceptance, of the cytokine concept of disease pathogenesis**

The extensive parallels that exist between the sepsis and malaria literature can be viewed from the perspective of the wide range of functionally-important inflammatory cytokines present in the circulation in both conditions (Table 1). This strengthens the view that the two diseases operate through very similar mechanisms. Nevertheless, a group working with African children has recently advocated that in order to understand falciparum malaria disease one must return to the pre-cytokine era. They evidently still espouse the idea that local vaso-occlusion uniquely sets the organ pathology of this disease apart from others with which it is clinically confusable, in particular sepsis [3-5,70]. Since the failure of treatment with corticosteroids to ameliorate severe cerebral malaria has...
been used as evidence against cytokine involvement [4], it warrants recalling that MIF, known to be high in this circumstance [71], antagonizes glucocorticoids [72], and nitric oxide (noting iNOS is also high [71]) inhibits glucocorticoid binding to its receptor [73]. Moreover, this data rationalizes the failure of corticosteroid as a treatment.

Analogy with other diseases is still an under-exploited tool in malaria. The original interest in TNF as a possible mediator of both innate immunity and disease pathogenesis in infectious disease came from analogies between the ability of BCG to protect against both tumours and intracellular protozoa [9]. When introducing the excess inflammatory cytokine concept in 1981 [15], a common case for malaria, gram-negative bacteria and the Jarisch-Herxheimer reaction, all of which withstood the test of time, was argued by analogy. As reviewed recently [21], the range of infectious diseases that come under the systemic inflammation umbrella now extends beyond bacterial diseases to those caused by rickettsias, protozoa other than malaria, and viruses. Moreover, increased circulating levels of TNF and functionally similar cytokines have been measured in the serum very soon after onset of illness in virtually all those infectious diseases in which it has been sought. In addition, essentially all of the signs and symptoms involved in the clinical confusability of malaria and other causes of fever have inadvertently reproduced during the era when rTNF was being injected in volunteers as an antitumour agent [74,75]. This includes headache, fever and rigors, nausea and vomiting, diarrhoea, anorexia, myalgia, thrombocytopenia, immunosuppression, coagulopathy and central nervous system manifestations, all of which have a literature on a mechanism through inflammatory cytokines. The rate, timing and intensity of cytokine (pro- as well as anti-inflammatory) release will vary in different disease states, and also between individuals, and provide them with somewhat distinctive clinical pictures, but the fundamentals remain. The clinical patterns generated are remarkably close, in that, at least in some populations, clinical features cannot predict a diagnosis of malaria from other causes of fever [76].

The principle extends beyond infectious diseases. A number of non-infectious states fit this pattern, with excessive release of pro-inflammatory cytokines producing a systemic inflammatory response. As in malaria and sepsis, metabolic acidosis [77,78], hyperlactataemia [79,80] and encephalopathy are seen in tissue injury syndromes such as heatstroke, trauma, and burns. As reviewed [21], all of these conditions are ripe for an explanation in terms of HMGB1, liberated from the nuclei of damaged tissue [81], setting the scene for a broad range of inflammatory cytokine release. Iatrogenic cytokine release syndromes, such as the side effects of OKT3 therapy [82], and acute graft versus host disease reaction [83,84] can also exhibit these changes, including a reversible encephalopathy. In both of these conditions the relevant pro-inflammatory cytokines are produced excessively, and where tested (side effects of OKT3 therapy [85], and acute graft-versus-host disease reaction [86]), prior exposure to neutralizing antibody directed against TNF prevents illness.

As with much research on neutralizing antibody to TNF, this outcome does not imply that TNF is more important than, for example, IL-1 in this context, since anti-IL-1 antibodies have rarely been tried. Blocking IL-1, and indeed IL-1 and TNF simultaneously, are in their infancy, but show promise [87,88]. Likewise, research into the disease aspects of LT, present in falciparum malaria, and relevant to the mouse model of cerebral malaria, is relatively ignored, largely through difficulty of obtaining reagents. Additional strong evidence for inflammatory cytokines and falciparum malaria being functionally intertwined comes from studies on variation in the human genome in Africa [89-91]. It is now accepted that falciparum malaria, historically the major fatal endemic disease in much of this continent, is associated with polymorphisms of these pro-inflammatory cytokines and iNOS, which are induced in this disease. Not surprisingly, sepsis and meningococcal disease have a similar literature [92,93]. Like any other DNA trying to survive, that of humans uses trial and error to adapt itself to its surroundings, leaving a trail of evidence as it does so.

In summary, illnesses arising from excessive systemic production of inflammatory cytokines include not just malaria and sepsis, but many more infectious, and non-infectious, diseases. Insights gained by recognizing the value of argument by analogy across this wide spectrum have been immense, and the general concept is now so firmly entrenched that, as noted earlier, its influence on the evolutionary effects of infectious disease is a research

Table 1: Some changes common to systemic inflammatory states in general, including sepsis and falciparum malaria

| Change                                |
|---------------------------------------|
| TNF, IL-1, iNOS and IFN-gamma, MIF, IL-10 and HO-1 raised |
| gamma-delta T cells raised            |
| MRPB (S100A8) and MRP14 (S100A9) raised |
| Procalcitonin raised                  |
| HMBG1 raised                          |
| ICAM, VCAM and p-selectin raised      |
| insulin resistance                    |
| hypoglycaemia                         |
| metabolic acidosis                    |
| hyperlactataemia                      |
| hyponatraemia                         |
| coagulopathy                          |
| thrombocytopenia                      |
| decreased red cell deformability       |
topic in its own right [26]. It would, therefore, be most unexpected were the illness of falciparum malaria, so clinically confusable with other infectious diseases, and known to generate the same inflammatory cytokines as they do, to arise from an unrelated mechanism [5,25].

Mitochondria unable to use available oxygen, a primary effect of inflammation

Inflammatory cytokines reduce ability of mitochondria to use oxygen

One of the many actions of the cytokines responsible for systemic inflammation is to disable oxidative phosphorylation within mitochondria. This is reflected in the hyperlactataemia commonly seen in severe infectious disease, and correlating with outcome. This is not to suggest that oxygen supply and its utilization are not often limited simultaneously, and interact. Indeed, if toxin is replaced by its downstream consequence (the effects of pro-inflammatory cytokines) such interaction was proposed for malaria by Meleney over 60 years ago [94].

Both sepsis and malaria researchers have shown that injecting TNF, the prototype inflammatory cytokine, increased in both diseases, causes hyperlactataemia [95,96], and blood lactate levels in severe malaria have proved to correlate closely with levels of both TNF and interleukin-1 [97]. Nevertheless, it is fair to say that sepsis researchers, without the tradition of a primary role for sequestration to defend, have been more receptive than malariologists to the systemic inflammatory explanation for altered carbohydrate metabolism, and more readily pursued it. Thus, they were more open than most of their malaria counterparts for the insights of the early 1990s, when newer techniques demonstrated that oxygen tension in tissues was actually increased (not decreased, as the literature predicted) in septic rats [98], patients [99], and pigs [100]. This implied an inability of mitochondria to utilize oxygen, forcing glycolysis to compensate, as best it can, for the energy deficit. The next insights came from groups who developed the cytokine-induced mitochondrial dysfunction model of disease [101-103] and, thus, provided an inflammation-based explanation for a shutdown of aerobic glycolysis, a consequent increased rate of glycolysis, and thus lactate production, metabolic acidosis and cellular energy depletion. In any disease with high levels of inflammatory cytokines this mimics poor oxygen supply. An important difference, however, is that the effects of the nitric oxide through which mitochondrial shutdown largely operates are reversible [104,105], whereas frank hypoxia, through vaso-occlusion, as evidenced by the stroke literature, is less so. Thus, the former, not the latter, is consistent with the marked reversibility of metabolic comas [106], a term advocated [21,107] to include human malaria.

This approach to understanding energy balance in sepsis has been followed successfully on a number of cell types, including hindlimb skeletal myocytes, gut wall cells, and hepatocytes. The wide range of tissues in which these concepts have been demonstrated adds to the arguments on systemic origins of lactate in sepsis and malaria. For example, inflammatory cytokines have been shown to cause contractile dysfunction [108,109] and also energy depletion [110,111] through effects, often mediated through induced nitric oxide [109,112], on cardiac muscle. Likewise, in diaphragmatic skeletal muscle there is evidence of cytokine-induced nitric oxide [113,114] and oxygen-derived free radicals [115] combining to form peroxynitrite [116,117] and this causing dysfunction of mitochondria in myocytes, leading to energy depletion and thus muscular contractile failure. The outcome here is to reduce the patient’s ability to counter acidosis by blowing off CO₂.

An additional pathway through which the inflammatory cytokines may reduce oxygen consumption is through peroxynitrate (ONOO⁻), a product of NO (from iNOS induced by these cytokines) and superoxide, overactivating poly(ADP ribose) polymerase-1 (PARP-1) [118]. This can deplete cellular stores of NAD⁺, and efforts to resynthesise it can deplete ATP as well (reviewed in reference [119]). Moreover, NAD⁺ is essential for glycolysis, so its depletion can be expected to impair glycolytic input into mitochondria. These concepts were reviewed in depth in a malaria context a few years ago [107].

Mitochondria starved of oxygen, a secondary effect of inflammation

This section summarizes the ways in which inflammatory cytokines indirectly limit the supply of oxygen to cells, and thus further reduce the capacity of their mitochondria to generate ATP through oxidative phosphorylation. There are good arguments from the basic literature that they may do so through directing sequestration towards organs that are particularly oxygen-sensitive. Being a new concept in the malarial world, this literature is examined here in some detail. In addition, anaemia, cardiac insufficiency, or insufficient circulating volume (see below, and Figure 3) can all be driven by inflammatory cytokines. Again, infectious disease in general is outlined before focussing on the particular case of falciparum malaria.

Inflammatory cytokines cause blood elements to adhere to endothelium

It is well accepted that upregulation by inflammatory cytokines of adhesion sites on endothelial cells invites susceptible circulating blood elements to attach to the inner wall of blood vessels. In many diseases, including malaria, this includes activated leukocytes and platelets, both of which play important roles in promoting proco-
agulant activity. For example, in malaria this activity is seen on circulating monocytes [120] and placent al macrophages [121], and the thrombin so formed enhances adhesion by increasing expression of CD36 on platelet surfaces [122].

Platelets and leukocytes
Platelets and leukocytes have been reported to adhere to endothelium in viral [123-125], bacterial [126,127] and protozoal infections, including the cerebral vasculature in paediatric falciparum malaria [71,128]. In particular, aggregated monocytes are a striking feature in malarial placentas [129], and a less dramatic finding in cerebral vessels [130], where they and the nearby endothelial cells stain strongly for iNOS [71]. These adhering elements can set up local foci of inflammation, generating more inflammatory cytokines (eg TNF in placentas [131]), including inflammatory cascades initiated by HMGB1 released from the adhering activated platelets [132]. Since HMGB1 increases are associated with severity of falciparum malaria [57], this could account for the potentiating effects of platelets reported in an in vitro model of endothelial activation by P. falciparum [133]. Along with the effects of systemic inflammation, these local inflammatory foci contribute to potentially fatal pathology, including loss of endothelial integrity, in infectious diseases in which circulating inflammatory cytokine levels are sufficiently increased. Notably, the range of complications seen in falciparum malaria, including coma, can therefore develop in sepsis [134], influenza [135], and sometimes vivax malaria [136,137], which show evidence of a high systemic inflammatory response, but have no possible involvement of sequestering parasites.

Parasitized red cells, an additional circulating adherent element in falciparum malaria
Although falciparum malaria shares with conditions such as severe bacterial disease much evidence for endothelial activation (eg adherence molecules [138,139] and circulating endothelial microparticles [140,141]) and its consequences (eg platelet and leukocyte adherence, above), it is distinguished from them by the presence of another obvious adherent object – erythrocytes containing mature parasites. From the biology of the erythrocytic phase of P. falciparum, vascular sequestration (endothelial adherence) of parasitized red cells, somewhere in the circulation, is inevitable for roughly the last half of the 48 hr erythrocytic cycle. Thus mature erythrocytic forms of the parasite are rarely seen in peripheral blood smears. This adherence was first noted in autopsy samples in the 19th century [142], and fuelled the widely (but not universally; see below) held view that much of the illness and pathology of this disease needed little explanation other than that offered through consequential impairment of microvascular flow. Thus, through the decades a common thread in proposals to explain falciparum malaria disease has been a primary role for tissue hypoxia caused by vasoocclusion by parasitized red cells. The presence of coma, hyperlactataemia, hypoglycaemia, and metabolic acidosis, all three consistent with a patient being forced to rely on anaerobic glycolysis for energy production, have encouraged this viewpoint. As summarized earlier, cytokine-induced cytopathic hypoxia can also explain these phenomena.

Microparticles in systemic inflammatory diseases
Microparticles are an intriguing component of the inflammatory system. First described in 1967 [143], they are a heterogeneous group of small membrane-coated vesicles released from many types of cells upon their activation or apoptosis, but differ from apoptotic bodies. They retain at least some functions of their cell of origin, which can include platelets, endothelial cells, and various leukocytes. Triggers for their release include TNF [144], and they are increased in the circulation in systemic inflammatory states such as sepsis and trauma [145,146], as well as inducing inflammatory cytokine release themselves [147]. Along with cytokine increases, endothelial activation and the activation and adhesion of platelets and leukocytes, microparticles provide further evidence for a common pathophysiology of sepsis, trauma, and malaria [140,148,149]. While microparticles enhance the general inflammatory activity in these circumstances, and their exploration within the context of malaria is novel, evidence that they are likely to prove to be a key to controlling malarial disease, any more than other inflammatory conditions in which they act as markers of severity, is so far lacking.

The interaction between cytokines and sequestration
Arguments against a primary role for sequestration in falciparum malaria illness
As noted earlier, sequestration is common in certain tissues of fatal cases of falciparum malaria. Nevertheless, a primary (ie prior to cytokine increase) harmful vasoocclusive role for sequestered red cells containing parasites does not, in our view, withstand close scrutiny. As a simple practical example, it requires the pathophysiology in patients equally ill from uncomplicated falciparum malaria and vivax malaria to be quite different. Parallels between vivax malaria and the outcome of injecting TNF into human volunteers [75,150], and increased levels of this and functionally-related cytokines in vivax patient sera [151] plus the non-sequestering nature of the parasitized red cells, are consistent with cytokines being sufficient to cause the illness of vivax malaria. This includes the occasional, but well documented, coma (see below). Logically, therefore, these cytokines are sufficient to explain uncomplicated falciparum malaria, a condition notoriously difficult to separate clinically from vivax
malaria [76]. This is consistent with occlusive parasitized red cells becoming an essential part of pathogenesis only when falciparum disease becomes more severe, and parasitized erythrocytes start to favour physiologically sensitive areas such as the cerebral vasculature. Alternatively, the total number of parasites, sequestered or otherwise, may, through the cytokine concentrations they generate, be what counts.

The erythrocytic life cycle dictates that sequestration is inevitably present before the onset of illness in malaria tolerant individuals, yet no information seems available on it taking any particular anatomical pattern in these people. Newer technology involving expression of luciferase by a defined stage of the life cycle, to date applied only to a mouse model (where it revealed intriguing results that warrant reading closely [152]), would be impractical in man. However, an indirect appreciation of the avidity, if not the location, of *P. falciparum* sequestration in asymptomatic, malaria-tolerant individuals (usually not even fever, yet parasite densities overlapping those seen in severe illness) comes from work done in Mali [153], in which blood smears were made three time a day, usually at 6 hr intervals, for 12–13 days. Some 3000 blood smears were examined. Fluctuations in parasite density between consecutive smears often proved to be massive and abrupt, and the authors concluded that such change could come only from mirror-image changes in sequestration rate, not through parasite multiplication. Transitory disappearance of parasites from the peripheral blood occurred at least once in all infected individuals (63 of 79 subjects). Such slide negativity was of short duration, unrelated to the cycle of trophozoite maturation, and attributed to dramatic increases in sequestration of existing parasites. To our knowledge this rapid oscillation between circulation and sequestration is not reported during untreated malarial illness. On this evidence, avidity of sequestration is lower in malaria-tolerant individuals than in patients, suggesting different controlling influences, with sequestration in the former group, but not in the later, being independent of inflammatory cytokines.

At autopsy, brain is often a favoured site of sequestration, but whether this preference occurs before coma onset, or develops while coma is progressing, has not been determined. Marked brain sequestration at death has not been a universal observation, and, as summarized by Maegraith [18], reports have accumulated since the 1920s on a mismatch, at autopsy, between cerebral sequestration and coma. Such evidence is still being presented [71], as discussed below. Impaired consciousness can occur in a range of systemic inflammatory states, being present in certain viral and bacterial diseases as well as malaria. Thus regarding parasite sequestration as a necessary mechanism for falciparum malarial disease ignores its close clinical and pathological similarity, in terms of metabolic changes and organs affected, to other diseases that also can cause impaired consciousness, but lack parasitized red cells. These conditions are now accepted to be systemic inflammatory states [76]. As summarized below, the broader literature is consistent with our novel proposal (below) that, in addition to the above post-sequestration activity of inflammatory cytokines, these mediators will have earlier determined, during severe illness, where most sequestration occurs.

For some time most adherents of the traditional sequestration-based view of falciparum malaria disease have accepted what they regard as secondary roles for inflammatory cytokines in falciparum malaria disease [154]. By these tenets, sequestration at sensitive sites, such as brain capillaries, leads to higher local concentrations of these cytokines near sequestered parasitized red cells, since these are the source of the parasite material that triggers their release, and endothelial cells and leukocytes are commonly their source. The importance of the site of sequestration to disease severity is thereby amplified, involving both vaso-occlusion and secondary cytokine effects, such as increased blood-brain barrier permeability [155]. This as a plausible aspect of the relationship between sequestration and inflammatory cytokines in falciparum malaria, but the concept outlined below is proposed here to be their major interaction in falciparum malaria.

**Influence of inflammatory cytokines on organ distribution of sequestration**

By far the bulk of the literature arguing for occlusion-induced pathology in falciparum malaria concerns its documentation in the brain [156] and placenta [157] in sick individuals, and it is timely to consider why these sites are favoured. Equally, why are these the main sites where monocyte accumulations occur? The following explanation seems highly plausible, and is testable. In brief, it suggests that sequestration favours the brain when circulating concentrations of TNF are high (ie when the patient is ill), but not before onset of illness, or in malaria tolerant individuals. The absence of mature forms on blood smears from these two groups implies that the capacity of parasitized red cells to sequester is quite robust, but sequestration is not focussed at harmful sites without raised inflammatory cytokines.

For over a decade there has been substantial evidence that inflammatory cytokines (TNF the most studied) increase expression on endothelial cells of the molecules to which parasitized erythrocytes adhere [158-160]. Being driven by cytokines whose detection and concentrations correlate with degree of illness, this increase can be expected to operate only in moderate to severe illness, not early in
infection, when TNF levels are undetectable, or in tolerant individuals, who have been argued to be refractory to malaria-induced TNF [161]. Blood smears confirm that sequestration occurs in these individuals. In the next paragraphs it is argued that during severe falciparum illness these cytokines (provided they have not killed the patient beforehand) could concentrate most sequestration to the sites familiar at autopsy.

TNF and interleukin-1 increase tissue factor expression on endothelial cells and mononuclear cells [162], thereby initiating pathways that generate thrombin (reviewed recently [163]), a molecule with many roles at the cross roads of inflammation and coagulation. When bound to thrombomodulin, a thrombin receptor on the endothelial cell surface, thrombin activates protein C, which can degrade Factor VIIIa and Factor Va, essential cofactors in

---

**Figure 1**
The proposed influence of differences in thrombomodulin levels on cytokine-induced expression of adhesion molecules on endothelial cells, and monocyte attraction, in different organs. (a) tissues with low endothelial thrombomodulin levels (b) tissues with high levels.
the activation of Factor X and prothrombin respectively [164]. These feedbacks play a central role in keeping coagulation in homeostasis.

It follows, therefore, that tissues in which thrombomodulin density on endothelial cell surfaces is lowest (brain least – indeed reported undetectable in an earlier study [165] – placenta next least, and other organs more [166]), will have more unbound thrombin left available for its other functions on activated endothelium. These include a ten-fold upregulation of adhesion molecules such as E-selectin by TNF [167], CD36 [122], intercellular adhesion molecule-1 (ICAM-1 CD54) and vascular cell adhesion molecule-1 (VCAM-1 CD106) [168] and, with implications for the observed accumulation of monocytes, monocyte chemotactic protein-1 (MCP-1) [169]. Moreover, thrombin – thrombomodulin complex formation will be low in tissues where endothelial thrombomodulin is low. Therefore protein C activation will be correspondingly low, and the negative feedback that controls TNF-induced thrombin formation correspondingly weak (Figure 1a), further enhancing concentrations of the above adhesion molecules. Levels of a range of inflammatory cytokines, including TNF, are high in supernatants of villous leukocytes from malarial placentas [170], so these principles should apply to the monocyte accumulations and heavy sequestration in this organ also.

Thrombomodulin also sequesters HMGB1, making it less available to activate RAGE (the receptor for advanced glycation endproducts, shared by this cytokine [171]), so it cannot express its full inflammatory potential [172], and thus generate a further wave of cytokines such as TNF. Hence a given concentration of HMGB1, a cytokine increased in serum in sepsis [53] and falciparum malaria [57] in proportion to degree of illness, can be predicted to exert more pro-inflammatory influence in brain and placental vessels, where more of it is functionally available because less of it sequesters on thrombomodulin. Unfortunately the intestinal blood vessels, another favoured site for sequestration in falciparum malaria, were not included in either the CD36 [122] or the thrombomodulin study [166]. The reverse of the arguments for brain serve to rationalise why sequestration is rare or absent in heart and skeletal muscle, tissues at the other (high) end of the thrombomodulin spectrum [166], and therefore with least free thrombin left available to upregulate sequestration sites during TNF-induced illness (Figure 1b). For these reasons harmful sequestration is best regarded as a consequence of increased inflammatory cytokine generation, as well as a potential way to focus release of these mediators at sequestration sites. In short, differential endothelial activation induced by high levels of circulating inflammatory cytokines could shift the emphasis of sequestration to potentially harmful loca-
tions where, through schizogony, it could then initiate the bulk of the next wave of cytokine release. As previously noted for neuron function in malaria [173], nitric oxide generated by iNOS induced by these cytokines could also plausibly explain the small intestine intussusception seen in most children dying with malarial coma in Malawi [174]. Nitric oxide has an essential role in an experimental model of this pathology [175], and iNOS is strongly induced in the small vessels of the jejunum (Figure 2) in this patient series.

**Anaemia**

As recently reviewed [176], critical illness associated with an inflammatory response invariably causes multifactorial anaemia. It has often been noted that anaemia could contribute to poor oxygenation of tissues in malaria [177] and there is general acceptance that it can be severe enough to reduce supply of oxygen to mitochondria to dangerously low levels. Thus it can be a major component of malarial pathology. Obviously a high parasite load indicates imminent widespread lysis, but anaemia does not correlate with parasitaemia, and sometimes is extreme when very few parasites are present.

**Poor red cell deformability**

Erythrocytes have a limited life, determined by how long they can remain flexible enough to squeeze through fenestrations in specialised vessels in the red pulp of the spleen [178]. A red cell that cannot pass this test is phagocytosed by adjacent macrophages, and lost. In health this loss is balanced by erythropoiesis, and haematocrit remains normal. Should red cells develop a premature poor deformability they are removed from the circulation correspondingly earlier. Like other cells, erythrocytes stay intact by constantly extruding Na\(^+\) in exchange for K\(^+\) through an energy-dependent "pump" in their cell membrane that was defined by the ability of certain digitalis glycosides to block it. This Na\(^+\)/K\(^+\) pump fails, and intracellular Na\(^+\) accumulates in (non-parasitized as well as parasitized) red cells during human [179] or monkey [180] malaria. These changes in ionic content of red cells have been observed in a sepsis model [181]. In another sepsis model [182], erythrocyte deformability could be shown to be caused by NO, an inhibitor of this membrane pump [183]. Since inhibition of the Na\(^+\)/K\(^+\) pump *in vitro* correlates with a reduced red cell deformability plus a parallel decrease in red cell filterability [184], any influence, such as NO [183,185], that inhibits this pump could potentially cause poor red cell deformability. Cytokine-induced iNOS provides a demonstrable [71] way for these changes to occur in severe malaria.

Originally recorded in uraemic patients, poor red cell deformability was observed in a small pilot study of malaria patients in 1985 [186]. Soon after it was recognized in sepsis [187,188], and subsequently studied in falciparum malaria with a view to understanding both circulatory obstruction [189] and anaemia [190]. There is good evidence that, when measured on admission, a severe reduction in red cell deformability is a strong predictor of malarial mortality [189], but whether this is cause and effect, or the two phenomena are simply inevitable co-travellers in a strong pro-inflammatory milieu, is unclear. It seems clear that poor red cell deformability (which affects parasitized and unparasitized red cells equally) and dyserythropoiesis can lead to severe anaemia in various diseases, particularly in chronic infections such as malaria. Its presence in vivax malaria [191] implies that its role in vaso-occlusion is less important.

Clearly, it would be useful if a shortened lifespan of red cells through their premature loss of membrane flexibility were compensated for by a faster rate of erythropoiesis. Unfortunately, the inflammatory cytokines that shorten the lifespan of the red cells also slow down their replacement, as outlined in the next section. Their combined effect on reducing haematocrit can be expected to be rapid.

**Dyserythropoiesis**

Because the parasite inhabits erythrocytes, which must burst if the parasite is to propagate, the obvious initial conclusion was that this source of red cell loss was central to the fall in haematocrit seen in this disease. As reviewed nearly 60 years ago [192], this fall was soon realised to be out of proportion to the number of red cells parasitized, so other factors were realised to contribute. Phagocytosis of unparasitized red cells was also recorded decades ago in monkey [193] and human [192] malaria, and for many years was regarded as sufficient explanation for this discrepancy. Others had been investigating dyserythropoiesis in the bone marrow of patients with falciparum malaria [194,195] and stressed its contribution to malarial anaemia. A group in Oxford [196], seeking an explanation for this dyserythropoiesis through an electron microscopy study of bone marrow, observed sequestration of parasitized red cells and argued that this caused the bone marrow dysfunction in falciparum malaria by restricting blood flow and thus inducing hypoxic changes. This idea proved inadequate, however, when this same group subsequently reported dyserythropoiesis and erythropagocytosis in vivax malaria, in which parasitized red cells do not sequester [197].

Twenty-five years ago our group proposed that TNF might cause the bone marrow depression seen in malaria [15]. Subsequently an undefined product in macrophage super-
natants [208], later identified as TNF [199], was found to inhibit the growth and differentiation of erythroid progenitor cells. When rTNF became available (but before it had become technically possible to assay for this cytokine in human serum) the dyserythropoiesis and erythrophagocytosis seen in terminal Plasmodium vinckei-infected mice were reproduced when a single injection of rTNF was given early in the course of the infection [200]. Phagocytosis of erythroblasts in bone marrow, a phenomenon also reported by Wickramasinghe et al. [196,197] in human malaria, was commonly observed [200]. Decreased erythropoiesis was subsequently reported in mice receiving continuous TNF infusions via implanted osmotic pumps, and increased erythropoiesis in malarial mice after injecting neutralizing antibody directed against murine TNF [201]. TNF-induced dyserythropoiesis has since been confirmed in rats [202], and mice expressing high levels of human TNF become markedly anaemic during malaria infections [203], even though parasite numbers, and therefore red cell loss post-schizogony, are considerably reduced.

The past decade has seen an expansion of this line of enquiry into human malaria, and also the number of cytokines, both pro-inflammatory and anti-inflammatory [204,205] in absolute amounts and ratios [206,207], that have been investigated in this context. It has been extended to include other pro-inflammatory cytokines, such as IL-12 [208] and FasL [40], and the role of the persistence of production of such cytokines in the anaemia of falciparum malaria infection has recently been examined [209]. Suppression of prostaglandin E2 during malaria infection has also been shown to have an important influence on these events [210].

A decade ago the mechanism of TNF-induced damage to human bone marrow cells was argued to be nitric oxide generated by iNOS induced by TNF [211]. More recently attention has focussed on another cytokine, MIF, downstream of TNF but also induced by agents other than TNF, as a cause of malarial dyserythropoiesis. Martiney and co-workers [212] found that MIF was enhanced in a mouse malaria model, and that MIF inhibited the formation of erythroid (BFU-E), multipotential (CFU-GEMM), and granulocyte-macrophage (CFU-GM) progenitor-derived colonies in vitro. Subsequently, MIF proved to be strongly detectable by immunohistochemistry in systemic, but not cerebral, vascular smooth muscle of fatal African paediatric sepsis and falciparum malaria [71]. It has very recently been found that sub-inhibitory concentrations of MIF synergise profoundly with TNF and interferon-gamma in inhibiting mouse erythroid precursor colonies [213]. These authors provide other data that greatly strengthens the case for a major role for MIF in malarial dyserythropoiesis. This work provides a timely warning against the reductionist approach to understanding the actions of cytokines in disease, which does not reflect the in vivo reality of a considerable number of these mediators being present simultaneously. Thus the slow replacement rate of red cells in malarial through the influence of inflammatory cytokines is now a well-established aspect of malarial disease pathogenesis. In summary, cytokines induced by malaria products are a major determinant of haemoglobin deficiency, and thus the rate at which oxygen reaches mitochondria in malaria.

Infection-induced dyserythropoiesis is not restricted to malaria. The first awareness of it in other infectious diseases appears to have been its description in HIV patients, plausibly as a consequence of opportunistic infections [214]. It has subsequently been observed in acute viral hepatitis B [215], simian [216] and human [217] parvovirus B19, visceral leishmaniasis [218] and dengue [219]. all conditions that are associated with increased levels of circulating TNF, and doubtlessly its regulators, such as MIF. As noted above, the effect on red cells of the combination of a lower rate of production and accelerated destruction can be expected to lead to severe anaemia. The literature on both these influences on red cells underline how widely the consequences of excessive inflammatory cytokines impinge on disease pathogenesis, and emphasise the conceptual limitations imposed by regarding falciparum malaria as somehow outside the sphere of these host-origin mediators [5,25].

Cardiac insufficiency

Cytokine-induced myocardial depression frequently accompanies severe sepsis (see [220]). Whereas it was previously considered a pre-terminal event, it is now clear that cardiac dysfunction, as evidenced by biventricular dilatation and reduced ejection fraction, is present in most patients with severe sepsis. It has been known for some time to be caused by soluble factor(s) released by macrophages exposed to endotoxin [221]. Once cloning of cytokines occurred its activity was attributed to IL-1, then also to TNF [222], then the two synergistically [223], and finally to IL-6 [224], a macrophage product induced by both of these mediators. A literature exists on these effects being minimised by blocking MIF, which reduces the feedback inhibition ofTNF production by glucocorticoids [225,226]. As discussed in above, excess inflammatory cytokines have been shown to cause cardiomyocyte mitochondrial dysfunction. Since TNF [38], IL-1 [38], IL-6 [39] and MIF [71] are all highly expressed in falciparum malaria, it can be expected that these cardiac-depressing activities would be acting in this disease as well as in sepsis. Evidence of this, in terms of circulating cardiac proteins, has accumulated in the past few years [227,228], although its clinical impact is yet to be evaluated. It may be present, but its potential clinical impact is over-ridden
by the effects of hypovolaemic shock, as summarized in
the next section.

Poor circulating volume
Insufficient intravascular volume is ultimately of concern
in disease because, through poor perfusion, it leads to
poor oxygen supply where it matters, the microcirculation
that feeds the mitochondria within the cells that form the
tissues the capillaries pass through. The major therapeutic
option is volume resuscitation. As recently reviewed
[229], it is under the control of a number of autoregulatory
mechanisms, and these are known to be disrupted in
sepsis. As well as the effects of changed red cell deforma-
bility, and adherence of platelets and leukocytes, as dis-
cussed above, variation in iNOS induction, leading to
more or less nitric oxide, essential for local degrees of the
vasodilation that perfusion depends on, are major con-
trolling factors.

Using a range of indicators, workers in Kenya have con-
firmed the older observation [230] that shock is not rare
in severe falciparum malaria [231], and that the haemody-
namic changes in children with severe malarial anaemia
complicated by the respiratory distress were more charac-
teristic of hypovolaemia than of biventricular failure
[232]. They have also demonstrated that while adminis-
tering albumin did not improve acidosis, it did reduce
mortality [233]. This conceptual approach has been stren-
uously questioned by others who detected only a mild fall
in total body water volume and extracellular water vol-
ume [234], as well as the relative rarity of severe hypoten-
sion in falciparum malaria compared to the shock that can
accompany trauma or sepsis [4]. However, local effects
may be much more important in falciparum malaria than
in sepsis – for example these could in part arise from
vasodilation being much more uneven in malaria than
sepsis because of patchy local foci of post-schizogony
malaria toxin release from sequestered parasites, and local
generation thus of the inflammatory cytokines that induce
endothelial iNOS [71]. It is recognized that during treat-
ment one would need to be cautious of fluid overload if
the patient displays evidence of cerebral oedema [235] or
cardiac insufficiency [236].

The detailed arguments on both sides of this debate are
beyond the scope of this review, except to note that they
are currently a major fault line between those who pro-
pose that malaria has a fundamentally similar pathophys-
iology to other acute systemic infections [21,233,237] and
those who see it as unique [238]. This issue cannot be
resolved until recognition is given to the need to research
the pathophysiology of malaria and other systemic infec-
tious states in parallel rather than, as at present, in iso-
lation.

From this and the previous section, it is not hard to visu-
alise the combined harmful effect on the patient when
systemic inflammation reduces oxygen supply to their
cells also makes these cells worse at using it. As shown in
Figure 3, the initiating pathophysiological lesion is the
onset of the systemic inflammatory response, and it is dif-
ficult, from the evidence, to envisage sequestering parasit-
ized red cells, per se, initiating malarial disease before it is
focussed to sensitive organs by systemic release of inflam-
matory cytokines. Sequestering parasitized red cells may
then, in part through locally released cytokines, exacer-
bate the illness if the patient survives long enough.

Practical consequences of these changes

Hyperlactataemia in malaria and other infectious diseases

Hyperlactataemia, a recognized marker of falciparum
malaria severity, is at the centre of controversies relevant
to the theme of this review. Its discussion requires some
basic biochemical background. The lactate anion has
complex roles in biology. Hyperlactataemia may be asso-
ciated with acidosis, a normal pH, or alkalosis [239], and
can occur in viral and rickettsial diseases [240], as well as
(see below) sepsis and malaria. In synopsis, most lactate
is generated during glycolysis, which essentially consists
of oxidising glucose, a six-carbon structure, into two three-
carbon molecules of pyruvate. This is reduced to lactate
through the action of pyruvate dehydrogenase, a reaction
that avoids pyruvate accumulating, and supplies NAD+ to
keep glycolysis going. Thus lactate can be formed as a
byproduct of glycolysis, which can occur in all metaboli-
cally active tissues and supplies ATP, albeit in small
amounts, independently of the presence of oxygen. Every
mole of glucose metabolised by anaerobic glycolysis to
carbon dioxide and water yields 4 moles of ATP, whereas
oxidative phosphorylation within mitochondria yields 32
moles of ATP. When oxygen usage falls (whether through
poor supply or poor utilisation) ATP generation falls, and
glycolysis is accelerated to compensate, as much as possi-
bly, for this energy loss. A consequence is oversupply of
the byproduct, lactate, but from a disease perspective this
is a side issue compared to insufficient ATP generation,
even though the two may correlate well. Enhanced glyco-
lysis under aerobic conditions can also increase lactate
production. The metabolic acidosis secondary to this fail-
ure of mitochondrial energy production, which high lac-
tate often accompanies, is a consequence of this energy
failure, and inevitably accompanies it in severe inflammat-
ory illnesses, including malaria and sepsis.

The body’s supplies of glucose, including stores of its pol-
lymer, glycogen, are not unlimited, so when glycolysis is
enhanced for any period it sooner or later runs out of fuel.
Glucoseogenesis fills the breech as much as possible, but
it soon fails because substrate supplies are limiting [241].
These events are reflected in the hypoglycaemia that has
often been reported in severe malaria [242] and sepsis [243,244]. When seen in this context hypoglycaemia in these diseases is no longer a primary cause of harm, such as when driven by hyperinsulinaemia, but an inevitable consequence of over-exuberant, typically anaerobic, glycolysis.

**Origin of the high circulating levels of lactate**

**Poor oxygen delivery to mitochondria**

In the 19th century an association had been noted between hypoxia and lactate accumulation in tissues, and a progression of logic through the physical exercise literature [245] led to lactate levels being seen not only as a marker for poor oxygen delivery in disease states, but also a consequence of it, and the cause of the acidosis. For some time hyperlactataemia has been regarded as a functionally relevant marker for a poor prognosis in both sepsis [246] and malaria [247]. It is now well accepted that hyperlactataemia correlates with a poor prognosis in paediatric falciparum malaria in Africa [97,177,248]. Although the sepsis world now discusses several origins for the lactate increase, including inflammation-induced mitochondrial dysfunction [103], in falciparum malaria it is still generally attributed to a reduced oxygen supply, mostly through microvascular occlusion by sequestered parasitized erythrocytes [70]. Unfortunately, the traditional conceptual approach (in which not only are acid properties attributed to the lactate anion but lactate and lactic acid are equated and used interchangeably) is dying hard in the malaria world.

Recent publications [4,238] promote the traditional view by arguing that lactate/pyruvate ratios are higher in malaria than in sepsis (but see [249]), and can therefore be explained only by hypoxia through vaso-occlusion [4,70]. However, it seems difficult to envisage a mechanism whereby insufficient oxygen reaching tissue mitochondria would generate higher lactate/pyruvate ratios than would its poor utilisation once there. Indeed an inadvertent positive control of mitochondrial dysfunction, seen as the side effects of treatment of HIV patients with nucleoside reverse transcriptase inhibitors that cause mitochondrial toxicity [250], can generate lactate/pyruvate ratios up to double that recently reported for severe malaria [4,70], and as high as any value reported for the severest adult cases in Thailand [251].

In order to test the possibility that sequestration is essential for these changes in skeletal muscle sections, tissues previously stained for other purposes [71,252] have been recently re-examined for adhering parasitized red cells. Since skeletal muscle is a tissue with one of the highest rates of oxygen consumption [253], it is predictably a large generator of lactate when anaerobic respiration dominates, whether triggered by oxygen insufficiency from vascular occlusion by sequestering parasitized erythrocytes or its adequate presence, but under-utilisation, through mitochondrial dysfunction. To address the vaso-occlusion possibility, 1–3 tissue sections from chest wall and/or diaphragm from each of 27 previously described [71] fatal malaria cases of African paediatric malaria were examined blind by three observers. Negligible sequestered parasites were observed in 24 of 27 cases (unpublished data), including 15 displaying a 3+ or more sequestration score in cerebral capillaries. In the light of the high thrombomodulin levels on endothelial cells in vessels in skeletal muscle [166], and its implications for expression of adhesion molecules (Figure 1b), this is not surprising. Unfortunately, lactate assays were not performed on this patient series. Nevertheless the high incidence of hyperlactataemia in fatal cases from this same population [254] implies that the incidence of skeletal muscle sequestration would need to be considerably higher than observed for this hyperlactataemia to have its origins in impeded oxygen delivery to this main glucose-consuming organ.

**Poor oxygen usage by mitochondria**

The concept termed cytopathic hypoxia [103], is now considered to be a major contributor to the pathogenesis of sepsis. This is consistent with the evidence from animal models that neutralizing TNF prevents [255] or reverses [256] metabolic acidosis in experimental sepsis, although the indirect action of TNF on oxygen delivery, through its effects on endothelial activation, and thus platelet and leukocyte adhesion, can also be expected to contribute in vivo. In addition, inhibiting TNF successfully treated the metabolic acidosis of sepsis in a double blind trial in premature infants [257], and immunizing mice against GPI, a malarial toxin selected for its capacity to induce TNF production, inhibited metabolic acidosis in a mouse malaria model [65]. These outcomes are equally likely to apply in any disease in which levels of the pro-inflammatory cytokines, including TNF, are raised, and metabolic acidosis occurs. Studies on muscle ATP depletion during severe sepsis in patient material [258] and experimental animals [259] have provided data consistent with these arguments. It would be most instructive to repeat these same experiments with muscle biopsies from malaria cases.

Since the inflammatory cytokines that cause mitochondrial shutdown are prominent in both sepsis and malaria [38,39] it can be inferred that this organelle dysfunction is an equally plausible cause of reduced ATP synthesis and increased lactate accumulation in both diseases, correspondingly diminishing the need to invoke the argument based on parasite-induced vascular occlusion to explain these changes in malaria. Moreover, the mitochondrial ultrastructural damage that correlates with lowered oxidative phosphorylation in a sepsis model [260] parallels that
Hypoxia and TNF both induce HIF-1

Hypoxia-inducing factor-1 (HIF-1) is a transcription factor that regulates activation of several genes responsive to low oxygen, including erythropoietin, vascular endothelial growth factor, glycolytic enzymes, and glucose transporters. These pathways need to be switched on whenever aerobic respiration is reduced, since they are essential for the body to generate as much ATP as it can. As evidence that both poor oxygen delivery and its poor utilization through the inhibitory effect of inflammatory mediators on mitochondria produce the same functional and, therefore, clinical end results, it should be noted that TNF [265] has, even in normoxic cells, the same HIF-1-inducing ability as has hypoxia [266]. This is predictable from the ability of TNF to shut down mitochondria (eg via the reversible effect of nitric oxide on cytochrome c [104]), the oxygen sensor that regulates HIF [267]. It provides a plausible explanation for the accelerated rate of aerobic glycolysis sometimes reported in sepsis [268], which can increase pyruvate and lactate levels in the absence of hypoxia [269].

Should cytokine-accelerated glycolysis occur under aerobic conditions, any resultant hyperlactataemia cannot be expected to be associated with acidosis, since protons are generated by ATP hydrolysis in mitochondria, and pH remains constant. The desirability of enhancing HIF-1 in systemic inflammatory states, in which category the presence of excess pro-inflammatory cytokine production places malaria, has recently been reviewed [270]. MIF, a pro-inflammatory mediator shown to be upregulated dramatically in a number of tissues in both severe falciparum malaria and sepsis [271], also accelerates glycolysis [272], so can be expected to contribute to the hypoglycaemia and hyperlactataemia of both diseases. As with HIF-1, both hypoxia [273] and TNF [42] upregulate MIF. Since anti-MIF antibody prevents hypoglycaemia and increases fructose 2,6-biphosphate in TNF (-/-) mice administered endotoxin, MIF is argued to act independently of TNF [42]. The relative importance and interaction of HIF-1 and MIF in this context have not yet been examined, but these activities of TNF and MIF nevertheless stress that an understanding of malarial disease needs a broader vision than simple vascular occlusion.

**Metabolic acidosis**

Metabolic acidosis is not a disease, but a symptom of a serious underlying process. As recently summarized [274], metabolic acidosis is defined as a decrease in blood pH secondary to a decrease in the bicarbonate concentration. The decrease in bicarbonate concentration may be secondary to an excess of acids that will consume bicarbonates, reflecting the open character of this buffering system, or to a loss of bicarbonates through the digestive or the renal route. These authors [274] note that importance of the metabolic acidosis may be appreciated by measuring the change in bicarbonate concentration from the normal, or the base excess, which gives a better assessment of the acid load because it takes into account the buffering of the non-bicarbonate systems. Despite the impression that much malaria literature gives, metabolic acidosis is not unique to this disease, being seen in viral, rickettsial and bacterial infections [240] as well as acute gastroenteritis, where its prevalence is higher than in malaria [275].

**Lactate: a cause, marker, or neither in the acidosis of malaria or sepsis?**

The notion persists in some malaria circles that excess lactate accumulation causes the metabolic acidosis that correlates with a poor clinical outcome, and therefore warrants therapeutic reduction [4,276]. Accordingly, these authors argue that lowering lactate levels with sodium dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenate kinase, would be sufficient to ameliorate the metabolic acidosis of falciparum malaria [4,276,277]. In our view the current literature on systemic inflamma-
tory diseases does not support this. To successfully treat metabolic acidosis DCA would need to increase oxygen consumption so that oxidative phosphorylation takes over from anaerobic glycolysis as the dominant ATP producer, and the protons generated when ATP is resynthesized from ADP and inorganic phosphate are reconsumed, increasing pH to normal levels [278].

A recent editorial in Critical Care Medicine [279] has lucidly summarized the key points of the mechanism of metabolic acidosis in sepsis, a condition that shares systemic inflammation and a range of its consequences with severe malaria (Table 2). These authors do not accept that lactate is the cause of the acidosis associated with hypoxia. Instead, they note the evidence that cellular acidosis during hypoxia, be it from limited oxygen supply or utilisation, arises from the hydrolysis of non-mitochondrial ATP. Every time a molecule of ATP undergoes hydrolysis, a proton is released. When oxygen is readily available, the products of this reaction, including protons, are recycled by mitochondria, and pH does not change. During hypoxia, however, the mitochondrial turnover rate drops below the rate of ATP hydrolysis, so protons are being produced faster than they can be recycled, and intracellular pH falls once buffering capacity is exceeded. Since these reactions are independent of lactate levels, merely reducing the level of this anion can therefore no more be expected to increase survival rate in falciparum malaria than it did in sepsis [280]. Indeed, it could in theory harm comatose patients, since there is evidence that lactate helps brain tissue survive hypoxic and hypoglycaemic episodes [281-283], and the lactate shuttle is proving to be how astrocytes protect neurons from metabolic stress [284]. Moreover, infusing enough lactate into patients with severe sepsis to cause hyperlactatemia did not cause acidosis, but an alkalosis [285].

Even when considerable lactate is generated under these conditions, it is now evident that other anions contribute much more than it does to the strong ion difference (SID) that, through influencing the body’s buffering capacity, has a considerable influence on acidosis in sepsis [286,287] and falciparum malaria [275,288]. Thus lactate, while to some degree a useful marker of metabolic acidosis in malaria and sepsis, seems not to be a cause of it, and therefore not a worthwhile therapeutic target.

The basic biochemistry of these pathways, in which protons are consumed when ATP regeneration occurs aerobically, but accumulate, lowering the pH, when ATP regenerates anaerobically, was elegantly set out by Dennis in 1991 [289]. Others have noted the difficulty in separating the effects of acidosis from those of hypoxia. Since much evidence points to hypoxic cells preferring an acidic environment [274], they question the wisdom of unthinkingly reversing acidosis. Establishing whether increased circulating lactate levels merely indicate a dominance of anaerobic glycolysis over oxidative phosphorylation in cellular energy generation, or whether it is innately harmful because its formation generates acidosis during oxygen-independent glycolysis, clearly has treatment implications.

**Effect of cytokine-induced defective respiratory muscle function on acidosis**

The importance of hyperventilation in helping to get rid of the excess CO2 that accumulates in metabolic acidosis, inactivating the bicarbonate buffering system, is well accepted in sepsis [290], and mechanical ventilation is used, as necessary, to facilitate its removal. The decrease in blood pH will depend on the PaCO2, which reflects the respiratory response to the metabolic disorder. As reviewed [274], if the metabolic acidosis is isolated and the patient can breathe unassisted, the importance of the hyperventilation is predictable, and simple formulas (the most common used being: PaCO2 = 1.5 [HCO3-] + 8) give the PaCO2 from the HCO3 value. This has a parallel in the clear lung severe respiratory distress of falciparum malaria, with deep stressful breathing, first described in paediatric patients in coastal Kenya a decade ago. This hyperventilation predicted over three times the likelihood of a fatal outcome than did coma alone, and was recognized as a consequence of the underlying severe metabolic acidosis [236,291]. Logically this should prove to be associated with high circulating levels of pro-inflammatory cytokines.

This need to breath heavily for an extended period demands much work of the muscles of the chest wall and diaphragm. Unfortunately, the pro-inflammatory cytokines that contribute to the acidosis also generate the inducible form of nitric oxide synthase (iNOS) in skeletal muscle in animal models of sepsis [292] and patients with this condition [117]. This is associated with poor muscle contractility, and thus a reduced capacity to self-correct acidosis through deep breathing. There is evidence to link this causally with inflammatory cytokine-induced nitric oxide and oxygen-derived free radicals causing mitochondrial dysfunction within the muscle of the diaphragm. This is in keeping with a similar functional role for the strong iNOS staining (Figure 4a) in chest wall skeletal muscle of fatal malaria and sepsis cases in African children [71]. Diaphragm skeletal muscle (unpublished) show the same picture (Figure 4b). Intense staining of skeletal muscle for iNOS in sepsis [293] and malaria [71] is consistent with the large difference recently found in nitrite/nitrate levels in the same tissue between survivors and non-survivors admitted into intensive care because of sepsis [258]. These samples were subsequently analysed paramagnetically, and changes consistent with a decreased concentra-
tion of mitochondrial Complex I iron-sulphur redox centres, which are particularly susceptible to nitric oxide, were linked to a fatal outcome [294].

More recently, the function of mitochondria in the diaphragm muscle of rats treated with bacterial endotoxin, which induces, in man as well as rat, the range of pro-inflammatory cytokines raised in both sepsis and malaria, has been examined in detail. A range of genes for proteins required for the mitochondrial electron transport chain are downregulated [295], resulting in reductions in various key subunits of Complexes I, III, IV and V of the transport chain, and a large fall in mitochondrial oxygen consumption [296]. Energy production and thus work ability of skeletal muscle is decreased. New data from these workers’ laboratory provides a rationale, in terms of preventing this mitochondrial dysfunction, for the haemoxygenase-1 (HO-1) has been reported to be greatly increased in key tissues in falciparum malaria and sepsis [252]. In brief, they found that administering an HO-1-inducing agent, haemin, before endotoxin, protects mice against endotoxin-induced mitochondrial dysfunction in diaphragm and cardiac muscle, including failed ATP generation [297]. They note the possibility of adopting this principle, if not this agent, in treating severe sepsis. Malaria is an obvious extrapolation worth exploring.

In summary, lactate is an approximate, but workable, marker for metabolic acidosis, which in turn is a good marker for hypoxia, the primary pathophysiological lesion in these diseases. Whether arising from (a) poor supply of oxygen to mitochondria (through vaso-occlusion, low circulating volume, anaemia or cardiac insufficiency) or (b) reduced cellular utilisation of oxygen through mitochondrial dysfunction (in response to severe systemic inflammation) the outcome is essentially the same. The presence of inflammatory markers and the nature of the illness implies that mitochondrial dysfunction is the constant, and poor oxygen delivery the variable, in a synergistic whole.

**Neurological involvement in malaria**

**Severe falciparum malaria – more than cerebral malaria**

The literature on this disease reflects the fact that by far the most cases occur in children in tropical Africa, although comparisons with the clinical picture in Papua New
Guinea, where children are said to experience a generally milder disease, [298] have been made. Over 60 years ago it was noted that the disease closely resembles that caused by fulminant bacterial or viral infections [299]. The clinical picture typically consists of three overlapping syndromes (impaired consciousness, severe respiratory distress, and severe anaemia), and the more of these present the higher the mortality. This complexity has been most clearly set out in the well-known Venn diagram based on observations made in coastal Kenya [300]. By using the term malaria with impaired consciousness, rather than cerebral malaria, the review from which this diagram is derived [300] avoids the pitfall of assuming that the altered brain function that can occur in severe falciparum malaria requires local histologically detectable changes that are unique to this condition. The other two syndromes common in this disease in African children, severe respiratory distress, an indicator of an underlying metabolic acidosis, and severe anaemia, are discussed below.

Cerebral vaso-occlusion and impaired consciousness in falciparum malaria
Cerebral malaria is certainly simpler to understand if one operates from the premise that, as Marsh and Snow so eloquently put it, severe malaria equals cerebral malaria equals cerebral microvascular sequestration [300]. Unfortunately, scientific argument on this question is muted, since publications are more readily obtained by dissecting the mechanism of sequestration than by questioning its importance. It is proposed here that, rather than consider the effects of systemic inflammation and cerebral vascular obstruction by sequestered parasitized erythrocytes as opposing theories of cerebral malaria (as the literature has until now), they are functionally inseparable, with harmfully located sequestration viewed as one of the many consequences of systemic inflammation. In addition, there are ample arguments against cerebral sequestration acting in isolation as a major cause of the coma of falciparum malaria.

Certainly coma can be a striking component of severe falciparum malaria, and sequestration plus accompanying microhaemorrhages a spectacular aspect of terminal brain histology. Yet, one without the other has commonly been reported, and a causal link questioned. An example from 60 years ago is by Kean and Smith [301], who collected 12 cases with clinical courses of cerebral malaria, yet cerebral vessels recorded as not being plugged. Another five cases in which cerebral vascular plugging was present had non-cerebral deaths.

Sequestering parasitized red cells are often an obvious histological feature, so some researchers [5,8,302] continue enthusiasm for vaso-occlusion being the prime mover of falciparum disease, with the cytokines of systemic inflam-
Infections include *falciparum* malaria [304,305]. Species that cause human disease often associated with symptoms that are similar to **Human babesiosis** is a haemoprotozoan tick-borne disease. The recent emphasis, when considering the pathogenesis of severe illness, on total parasite load (mediators of host origin), rather than the degree of sequestration they cause [174], is a welcome development towards acceptance of the cytokine concept.

Human babesiosis is a haemoprotozoan tick-borne disease often associated with symptoms that are similar to *falciparum* malaria [304,305]. Species that cause human infections include *Babesia microti*, the mouse form of which is functionally allied with several mouse malaria species, in that they cross-protect and cause similar pathology [306]. Complications in human *B. microti* infection can include altered mental status, adult respiratory distress syndrome, renal insufficiency, disseminated intravascular coagulation (DIC), gastrointestinal bleeding and multi-organ failure [304,305]. These changes have been assumed, in parallel with the tradition for human malaria, to be caused by vascular occlusion. Since *B. microti* does not sequester in mice, a recent opportunity was taken to see if it behaved differently in tissues from a patient infected with this parasite. Sequestration was not observed [307]. The implications, from this single case study (a splenectomised individual, but the pathology can be equally complex in intact and asplenic patients [308,309]), implies that another mechanism, such as high cytokines [310], must be the cause of the *falciparum*-like pathology of this disease. It is also appropriate to note here that selection for degree of sequestration of *Babesia bovis*, widely regarded as a parallel for the vaso-occlusive model of *falciparum* malaria, did not produce parasites that generated more virulent infections in cattle [311].

As English and co-workers have noted, the low mortality when coma occurs in the absence of anaemia or markers of metabolic acidosis indicates that a localised cause of coma, such as cerebral vaso-occlusion, is very unlikely to be a sole cause of mortality without a systemic inflammatory input, and that coma in acidotic children might well have a different mechanism than in those with brain lesions only [312]. Nevertheless, loyalty to the vaso-occlusion explanation of malarial coma and death can be strong, leading, in one instance, to several interpretations of the same autopsy series [8,71,313]. One version [8] discounts evidence of systemic inflammation [71] and argues that cerebral malaria should be redefined as an autopsy-based, cerebral sequestration-defined entity rather than, as is usual, a clinical syndrome with the capacity to encompass a range of mechanisms, local or systemic, thought able to generate the same clinical endpoint [300,314]. The need to treat ill individuals and conduct clinical research in circumstances when patients survive, or autopsies are impractical, ensures that the present standard clinical definition is not likely to be displaced. Indeed in a recent publication on microparticles [140] the laboratory seeking to give cerebral malaria an autopsy-based definition [8] itself reverted to the standard definition, of necessity. Final decisions on what can be learnt from the only large African paediatric autopsy study to date await publication of the autopsy reports from this study, and correlation with the information already in the literature on these cases [71,252].

If cerebral sequestration proves not to become prominent until soon before death, might it, though present at autopsy, have been incidental to the fatal outcome? There is now increasing agreement [69,314,315] with insights, now decades old [19,316], that the coma of *falciparum* malaria can often be a cytokine-induced metabolic encephalopathy. Thus, a consensus appears to be developing that, despite how technically impressive knowledge of the mechanism of adhesion is becoming [317], the rapid and usually complete resolution of cerebral symptoms in most (presumably even those with cerebral sequestration) who recover is inconsistent with a primary role for mechanical microcirculatory obstruction. This adds to the evidence that it seems ill-advised to regard fatal coma in malaria-infected African children as having been caused by malaria only when sequestration is present in brain sections [8].

Functional evidence, in terms of reduced blood flow, has been sought for cerebral vascular occlusion being important in the pathogenesis of disease during *falciparum* malaria, both in Thai adults [318] and African children [319], but not found. Indeed, increase in cerebral venous pO$_2$ was noted at the time [318] to be consistent with an inability to utilise the oxygen delivered, a cytokine-
dependent concept discussed above. Another approach has capitalized on variation in the degree to which different strains of parasite cause adhesion of the red cell they inhabit. One study found no association between disease severity and adherence to CD36, and significance for ICAM-1 when anaemic cases are discarded [320], while another reported a significant inverse correlation of illness severity with both binding sites [321]. In contrast to the traditional story, this implies that sequestration could be associated with a less pathogenic infection. The tools to test anti-PFEMP1 in this context have been available for several years, and demonstrated to work in the human/severe combined immunodeficiency (SCID) mouse chimeric model [322], but to our knowledge there are no reports of them having been tested clinically.

The outcome of the recent study in African children referred to above [71] provides a very useful window on "pure" falciparum malaria compared to cases in which death may have occurred sooner because of another contributing factor. One third of the 32 fatal clinically-defined cerebral malaria cases examined histologically had little or nothing to see in the brain by way of sequestered parasites, monocyte clusters, microhaemorrhages, or iNOS or HO-1 staining that would have indicated the advent of local vascular inflammatory change at the time of death. Some had high parasitaemias [71] and strong gut vessel sequestration of parasitised red cells (unpublished). Yet this third was clinically diagnosed as cerebral malaria on the same criteria as were the rest, presumably providing a modern day example of the cases described by Kean and Smith [301]. Two of this group had severe anaemia, and others, on autopsy, proved to have non-malarial changes, such as bacterial pneumonia or patchy hepatic necrosis. These changes were judged to have contributed to the fatal outcome, leading to an earlier autopsy, in malaria terms, than would have happened in the absence of this joint cause of death. As discussed [107], this group, one third of the cases, gives an useful insight into what may have been happening within the cerebral vasculature of the rest of these patients, the "pure" malaria cases, after they had become comatose, but were still some time away from death, when cerebral sequestration, monocytes, platelets and microhaemorrhages were present [71].

Intriguingly, these comatose malaria cases with no appreciable change in their brains nevertheless showed appreciable systemic evidence of inflammation, as demonstrated by the marked evidence of iNOS, MIF [71] and HO-1 [252] expression elsewhere. These systemic changes were shared with the comatose sepsis cases in the series – indeed there was nothing to tell them apart immunohistochemically, and the depth of coma was of the same order in both groups. The outcome in most of these cases was likely to have been determined by the acute downstream effects of inflammatory cytokines, including energy depletion and metabolic acidosis, although data that could have provided this degree of detail was unavailable from these individual cases. The rest of the cases, with a range of degrees of sequestration and evidence of systemic inflammation, are discussed in detail in a recent review [21].

From the principles that form the stroke literature, individuals with appreciable cerebral sequestration are likely to be over-represented in fatal cases. Likewise, comatose patients who do not develop local brain changes, including overt sequestration, might well have a higher chance of survival, and are thus under-represented in the fatal comatose cases from which are drawn the histology samples that are the basis of the sequestration theory of cerebral malaria. Recent work on mouse cerebral malaria, caused by Plasmodium berghei ANKA, has used new experimental tools to address this question, and in a detailed and convincing study goes against conventional wisdom, disassociating cerebral pathology from sequestration [152]. This research warrants being given due weight by those advocating the relevance of this model to the primary lesion in human cerebral malaria. The next section of this review provides examples of cytokine-induced metabolic encephalopathies that cast light on the coma of falciparum malaria.

Systemic inflammation, no parasite sequestration, yet still encephalopathy

To understand cerebral functional impairment, including coma, in clinically defined cases of falciparum cerebral malaria that show minimal if any sequestration on brain sections [18,71], it warrants considering which other infectious systemic diseases can cause a focal encephalopathy. In 2002, Kunze provided an excellent overview [323] in which he discussed metabolic encephalopathies in general under hypoxic, ischaemic, systemic (including infectious) and toxic groupings. It seems clear that changes occurring in falciparum malarial encephalopathy qualify it for inclusion in several of these categories without the presence of the sequestered parasites. This 2002 review provides adequate material from which to argue that an intense inflammatory response, in the sense of a strong systemic pro-inflammatory imbalance of cytokines, as distinct from the traditional cellular influx, can cause a cerebral syndrome essentially the same as that observed in severe falciparum malaria.

Cerebral malaria caused by Plasmodium vivax

Probably the most immediately relevant of these encephalopathies to a discussion on falciparum malaria (for it is just as validly termed cerebral malaria) is the reduced consciousness sometimes seen in severe vivax malaria, caused by a parasite accepted not to sequester. For many years
such reports were dismissed as undiagnosed double infections (vivax plus falciparum), but evidence from geographical areas where falciparum malaria was not present, plus new specific diagnostic techniques, have led to an acceptance of the concept. For instance, in 2002 Beg collected the records of 41 such cases [136], and a more recent study described 11 such patients [137]. They exhibited cerebral symptoms, renal failure, circulatory collapse, severe anaemia, haemoglobinuria, abnormal bleeding, acute respiratory distress syndrome and jaundice, all of which are commonly associated with falciparum malaria. Vivax malaria can demonstrate a strong systemic inflammatory response [324], but this was not examined in these cases. Anstey and co-workers have compared a range of pulmonary functions in vivax and falciparum infections, and concluded that a common underlying inflammatory mechanism was probably acting [325].

Sepsis encephalopathy
As in falciparum malaria, mental confusion and obtundation can be early signs of the sepsis syndrome, and altered mental status is associated with a higher mortality [326]. The clinical features of sepsis encephalopathy vary from mild confusion to coma, one study of 69 sepsis cases finding 32 with severe functional changes [323]. This study showed that in sepsis the brain fails in parallel with other organs, and that the severity of the systemic illness, rather than the encephalopathy per se, accounts for the outcome in individual patients, although the brain proves to be a sensitive indicator of severe generalised septic illness. More recently, Morita and co-workers [327], studying 27 acute sepsis encephalopathy cases, including some associated with influenza (see next section), found inflammatory cytokines to be higher in the serum than in the cerebrospinal fluid. They also reported that high serum inflammatory cytokine levels at the initial stage of illness, and the good correlation of those levels with outcome, suggest that systemic inflammation has a significant role in the blood-brain barrier permeability, general vascular leakage and multiple organ dysfunctions in patients with acute encephalopathy. Evidence of causality has been observed in an animal model in which prior administration of a neutralizing antibody to TNF prevented the sepsis encephalopathy, generated through experimental pancreatitis, a standard functional example of sepsis [328].

Influenza encephalopathy
Probably the best documented encephalopathy which closely parallels the changes that may occur in falciparum malaria is the form sometimes seen in severe influenza. It is most frequently reported in children in Japan and other Asian countries, and provides a close functional match indeed. As in malaria, the infectious agent is not neuroinvasive [329]. Seizures and coma occur after high grade fever [330], commonly accompanied by thrombocytopenia [330], and metabolic acidosis and hyperlactataemia in severe cases (T. Ichiyama, pers. comm.). TNF, IL-6, sTNFRI, and soluble E-selectin are increased in serum and CSF [331,332], and serum nitrite/nitrate levels are increased [333]. Vascular endothelial cells are damaged [135] and multiple organ failure and neurological sequelae occur [334], as does brain oedema associated with damage to the blood-brain barrier [335]. More detailed examination of brain has revealed apoptosis of neurons and glial cells [335], as well as histological evidence of active caspase-3 [335], and caspase-cleaved PARP [335]. As summarized in Table 2, these changes are all demonstrable in the encephalopathy of falciparum malaria, implying that in this disease sequestering parasitized erythrocytes may accompany, rather than cause, them. The concept of cytokine-induced mitochondrial respiratory failure, as discussed above, is a topic of interest in influenza encephalopathy research [336]. It is noteworthy that circulating levels of cytochrome c, released from damaged mitochondria, are increased in both sepsis [337] and influenza encephalopathy [332], in which it has proved to have better prognostic predictive value than do inflammatory cytokines [338]. This provides a strong case for it also being tested in severe malaria.

It is feasible, but to our knowledge not yet investigated, that increased inflammatory cytokines might cause some degree of poor brain microcirculation in influenza encephalopathy, as well as some local enhancement of inflammation, through inducing adhesion of platelets and monocytes. Were this so, it would be reasonable to regard such changes as pathology-enhancing accessories after the event was under way rather than prime instigators of it. In summary, influenza encephalopathy demonstrates that a syndrome inseparable from cerebral malaria can occur without invoking adherent parasitized red cells. The evidence suggests that the CM(A) group of paediatric malaria cases [71], and well as the earlier Kean [301] and Maegraith [18] examples, are conceptually the same as influenza encephalopathy.

Hyperphenylalaninaemia and IDO induction in systemic infectious diseases
Phenylalanine is an aromatic amino acid required, in controlled concentrations, for the normal synthesis of various monoamines essential for brain function. Several types of genetic defects of phenylalanine hydroxylase or tetrahydrobiopterin metabolism can elevate its plasma levels to pathological levels. If not corrected by a low phenylalanine diet from an early age, chronic excess of this amino acid can cause an encephalopathy associated with seizures, and in time retards brain development and causes various functional deficits [339]. Transient hyperphenylalaninaemia can be induced by endotoxin [340] or TNF.
so not surprisingly is a component of the various systemic inflammatory states. For example phenylalanine is reported to be increased (20.9-fold in CSF and 7.5-fold in plasma) in septic encephalopathy [342]. In another study the increase correlated with APACHE II score [343]. The same increase in severe falciparum malaria, particularly in comatose children [344,345], is entirely consistent with this condition also being another systemic inflammatory state, a main theme of this review. Therefore, as in sepsis encephalopathy, a reasonable case can be made for transient hyperphenylalaninaemia to be an additional inflammation-associated mechanism for encephalopathy in malaria, independent of vascular occlusion. So too, as reviewed recently elsewhere [315], does the induction, by inflammatory cytokines, of indoleamine 2,3-dioxygenase (IDO), a rate-limiting enzyme in the L-tryptophan-kynurenine pathway, which converts L-tryptophan, an essential amino acid, to N-formylkynurenine. The observations that this also occurs in sepsis [346] and trauma [347], also strengthen our original case [348] for organ failure in malaria, sepsis and trauma having the same pathophysiology.

Seizures in encephalopathies
As noted above, hyperphenylalaninaemia warrants serious consideration as a contributor to the seizures observed in septic encephalopathy and cerebral malaria. So too does zinc chelation by S100 proteins. Our 2003 studies on tissue sections from East African children [71,252] included a number of cases of severe sepsis encephalopathy, without malaria parasites but with bacterial pathogens (e.g. Escherichia coli and Salmonella enteritidis) present. Certain tissues exhibited immunohistochemical evidence (iNOS, MIF and HO-1) of intense systemic inflammation. S. enteritidis is a pathogen known to alter brain function, causing a diffuse encephalopathy, including seizures as part of a systemic syndrome [349]. Current ideas on the origin of septic encephalopathy, including blood-brain barrier opening and S100B as a possible marker for the degree of pathology, have been discussed recently [350]. S100B has also been reported to be increased in cerebral malaria in Vietnamese adults, where it was associated with seizures [351].

Serum and CSF Zn levels decrease during infectious diseases, and this decrease is more significant in patients with febrile convulsions [352]. Both S100B and other members of the S100 protein family, including S100A12, are strong chelators of zinc [353,354]. S100A12 is an IL-1 and TNF-inducible mediator found to be increased in severe malaria serum (M. Griffith, C. Geczy and I. Clark, submitted) and detected in monocytes in cerebral vessels in falciparum malaria and Salmonella enteritidis sepsis (Figure 5). Cerebral zinc homeostasis is essential for normal brain function [355] and, of relevance to seizures, zinc induces the spontaneous depolarising synaptic potentials that normally dampen synaptic transmission. These potentials can be inhibited by zinc chelation [356]. These authors

![Figure 5](http://www.malariajournal.com/content/5/1/85)

**Figure 5**
Immunohistochemical staining of cerebrum of (a) African paediatric control (MP41), (b) Salmonella enteritidis (MP12) and (c) P. falciparum (MP6) to detect S100A12. Techniques (DAB, haematoxylin) as in reference 71. Antibody courtesy of Dr Carolyn Geczy. See Table 1 of ref. 71 for case details. Unpublished data.
note the implications of this result for understanding seizures in young children with acute dietary zinc deficiency. The concept warrants exploration in the seizures in the encephalopathies of sepsis, influenza and malaria in young children, since S100B and cytokine-induced S100 proteins can be expected to act like these synthetic zinc chelators [356] and generate local areas of functional zinc deficiency.

**Inflammatory cytokines offer insights into differences between childhood and adult malaria**

There are real differences in the nature of the disease in children and adults. For example, severe anaemia is much more common for a given parasite density in young children than in older children and adults [300], and seizures follow a similar pattern [357]. In contrast, cerebral malaria is less common in the very young, and the pulmonary and renal complications seen in adults are very uncommon in children [300]. Moreover, children can experience a type of clear lung respiratory distress not reported in adults [358], implying a more severe metabolic acidosis driven by the need to blow off excess CO2 and restore normal pH. This is consistent with hypoglycaemia (from high glucose consumption feeding the anaerobic state that is causing proton accumulation) being a characteristic of childhood malaria more than of adult cases.

The cytokine theory of disease provides directions that could lead to an understanding, currently lacking, for these age differences. For instance, generation of nitric oxide, which has been instrumental in the Na+/K+-ATPase inhibition thought to cause poor red cell deformability, and thus shorten erythrocyte life span, is higher in younger children [359,360]. Additional nitric oxide generated by a systemic inflammatory response would add to this higher base level, reducing red cell deformability correspondingly more in the very young. This could be tested. Likewise, pulmonary and renal organ failure being common in severely affected adults, but virtually absent in children [300], has an exact parallel in the age differences for the inflammatory response that follows trauma [361]. This has been explained in terms of the different balance of inflammatory cytokines generated from normal peritoneal cells collected from children vs adults [362,363]. There seems no reason why these data, derived from normal human cells, should not be equally applicable to any human systemic inflammatory state, including malaria. This enhanced anti-inflammatory response of young children can also be expected to minimize the proposed focussing of sequestration during severe illness in this age group, contributing to their low incidence of cerebral malaria [300].

**Conclusion**

In broad terms, the essential mechanism of death in falciparum malaria disease is agreed by many researchers: a functional tissue hypoxia that forces an unsustainable dependence on anaerobic metabolism. An unresolved key question is whether the tissue hypoxia arises (a) because insufficient oxygen reaches the mitochondria through either vascular occlusion from sequestered parasitized red cells acting alone, or in combination with anaemia or (b) because excessive release of inflammatory cytokines, induced by malarial toxin(s), render mitochondria unable to use oxygen to generate energy from oxidative phosphorylation. Although wearing contemporary clothes, this is the same dichotomy that was present a hundred years ago. Current basic literature suggests that inflammatory cytokines are very much the dominant partner, having amongst their powers the capacity to shut down bone marrow, make red cells prematurely poorly deformable, and channel sequestration towards certain sites, dictated by innate local thrombomodulin concentration (Figure 1). Thus cytokines and poor oxygen delivery should not be viewed as alternative theories of malarial disease pathophysiology. Instead, the latter is one of the consequences of the former.

**Acknowledgements**

This research was funded by the National Health and Medical Research Council of Australia and the Ben Brown Fund. The authors gratefully acknowledge, chronologically, Frank Cox, Jean-Louis Virelizier, Betsy Richards, Brian Maegraith, Chris Bryant, Michael Boyle, Kirk Rockett and Melissa Awburn for invaluable input and encouragement.

**References**

1. Reid RA, Moyle J, Mitchell P: Synthesis of adenosine triphosphate by a proton motive force in rat liver mitochondria. *Nature* 1966, 212:257-258.

2. Mitchell P: Proton current flow in mitochondrial systems. *Nature* 1967, 214:1327-1328.

3. Planche T, Agbenyega T, Bedu Addo G, Ansong D, Owusu Ofori A, Micah F, Anakwa C, Asafo Agyei E, Hutson A, Staapoolwe PW, Krishna S: A prospective comparison of malaria with other severe diseases in African children: prognosis and optimization of management. *Clin Infect Dis* 2003, 37:890-897.

4. Planche T, Dzeing A, Ngou Milama E, Kombila M, Staapoolwe PW: Metabolic complications of severe malaria. *Curr Top Microbiol Immunol* 2005, 295:105-136.

5. Planche T, Krishna S: Severe malaria: Metabolic complications. *Curr Mol Med* 2006, 6:141-153.

6. Cain BS, Meldrum DR, Harken AH, McIntyre RC: The physiologic basis for anticytokine clinical trials in the treatment of sepsis. *J Am Coll Surg* 1998, 186:337-350.

7. Beigel H, Farrar H, Han AM, Hayden FG, Hyer R, de Jong MD, Lochinardat T, Tien NTK, Hien NT, Hien TT, Nicosol A, Touch S, Yuen KY: Current concepts – Avian influenza A (H5N1) infection in humans. *N Engl J Med* 2005, 353:1374-1385.

8. Taylor TE, Fu WJJ, Carr RA, Whitten RO, Mueller JG, Fosiko NG, Lewallen S, Liomba NG, Molyneux ME: Differentiating the pathologies of cerebral malaria by postmortem parasite counts. *Nat Med* 2004, 10:143-145.

9. Clark IA, Wills EJ, Richmond JE, Allison AC: Suppression of babesiosis in BCG-infected mice and its correlation with tumor inhibition. *Infect Immun* 1977, 17:430-438.

10. Butcher GA, Bannister LH, Mitchell GH: Immune damage to intracellular malaria parasites. *Trans R Soc Trop Med Hyg* 1976, 70:11.
11. Butcher GA, Mitchell GH, Cohen S. Antibody mediated mechanisms of immunity to malaria induced by vaccination with Plasmodium falciparum. Immunology 1978, 34:77-82.
12. Lanhamne J, Butcher GA, Mitchell GH, Cohen S. Preliminary investigations on the role of the spleen in immunity to Plasmodium knowlesi malaria. In Role of the spleen in the immunology of parasitic diseases Schwabe, UNDP/World Bank/WHO, Basel, 1979:205-225.
13. Miller LH, Powers KG, Shiroishi T: Plasmodium knowlesi: functional immunity and antimerozoite antibodies in rhesus monkeys after repeated infection. Exp Parasitol 1977, 41:105-111.
14. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: Possible importance of macrophage-derived mediators in acute malaria. Infect Immun 1986, 50:9-13.
15. Clark IA, Virelizier J-L, Carswell EA, Wood PR: Possible importance of macrophage-derived mediators in acute malaria. Immunology 1982, 46:755-758.
16. Clark IA: Monokines and lymphokines in malarial pathology. Atiopein Trop Med Parasitol 1987, 81:577-585.
17. Maegraith B: Pathological Processes in Malaria and Blackwater Fever. Blackwell, Oxford, 1948:367-369.
18. Langhorne J, Butcher GA, Mitchell GH, Cohen S: Suggested importance of monokines in pathophysiology of endothrix shock and malaria. Klin Wocherschr 1982, 60:756-758.
19. Clark IA: Pathological Processes in Malaria and Blackwater Fever. Blackwell, Oxford, 1948:367-369.
20. Clark IA: Cell-mediated immunity in protection and pathology of malaria. Parasitol Today 1987, 3:300-305.
21. Clark IA, Cowden WB: Is TNF a key to acute infectious illness? Today’s Life Science 1989, 1:726-29.
22. Clark IA, Alleve LA, Mills AC, Cowden WB: Disease pathogenesis in malaria and clinically similar conditions. Clin Microbiol Rev 2004, 17:509-539.
23. Rosen RC: The pathogenesis of sepsis. Ann Intern Med 1991, 114:457-69.
24. Cheung CY, Poon LLM, Lau AS, Luk W, Lau YL, Shortridge KF, Gordon S, Guan Y, Peiris JS: Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease. Lancet 1997, 349:1081-1087.
25. Schofield L, Grau GE: Complexity of immunological processes in the pathogenesis of malaria. Nat Rev Immunol 2006, 6: doi: 10.1038/nri1858-26.
26. Graham AL, Allen JE, Read AF: Evolutionary causes and consequences of immunopathology. Annu Rev Ecol Evol Syst 2005, 36:373-397.
27. Clark IA, Hunt NH, Butcher GA, Cowden WB: Inhibition of murine malaria (Plasmodium chabaudi) in vivo by recombinant interferon-gamma or tumor necrosis factor, and its enhancement by butylated hydroxyanisole. J Infect Immun 1987, 139:3493-3496.
28. Rockett KA, Awbourn MM, Cowden WB, Clark IA: Killing of Plasmodium falciparum in vitro by nitric oxide derivatives. Infect Immun 1991, 59:3280-3283.
29. Muzir-Lunquera ML, dos Santos-Neto LL, Tosta CE: Influence of tumor necrosis factor-alpha on the ability of monocytes and lymphocytes to destroy intraerythrocytic Plasmodium falciparum in vitro. Cell Immunol 2001, 208:73-79.
30. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyzk C, Bryden M, Ciocon N, Anderson K, Makhankijcharoen Y, Martin LB, Wilson D: Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002, 360:610-617.
31. Van Hensbroek MB, Palmer A, Onyiorah E, Schneider G, Jaffar S, Dolan G, Memming H, Frenkel J, Enwere G, Bennett S, Kwiatkowski D, Greenwood B: The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J Infect Dis 1996, 174:1091-1097.
32. Fisher CJ, Agostin JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RMH, Benjamin E: Treatment of septic shock with the tumor necrosis factor receptor-Fc fusion protein. N Engl J Med 1996, 334:1697-1702.
33. Feldmann M, Maini RN: TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2003, 9:1245-1255.
34. Clark IA, Allison AC, Cox FE: Protection of mice against Babesia and Plasmodium with BCG. Nature 1976, 259:309-311.
35. Clark IA: Protection of mice against Babesia microti with cord factor, COAM, pyrazon, gluran, Salmonella and Listeria. Parasite Immunol 1979, 1:179-196.
36. Clark IA: Resistance to Babesia spp. and Plasmodium sp. in mice pretreated with an extract of Coxiella burnetii. Infect Immun 1979, 24:319-325.
37. Clark IA, Gray KM, Rockett EJ, Cowden WB, Rockett KA, Ferrante A, Aggarwal BB: Increased lymphomycin in human malarial serum, and the ability of this cytokine to increase plasma interleukin-6 and cause hypoglycaemia in mice – implications for malarial pathology. Trans R Soc Trop Med Hyg 1992, 86:602-607.
38. Kowalski D, Hill AVS, Sambou I, Twumasi P, Castracane J, Manogue KR, Cerami A, Brewster DR, Greenwood BM: TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 1990, 336:1201-1204.
39. Kawai H, Hemmer C, Van Damme J, Gruss H-J, Dietrich M: Elevated tumour necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med 1989, 87:139-143.
40. Issifou S, Mavounou E, Borrmann S, Bouyou Akosse MK, Masseguie PB, Reimsner PG, Ntoumi F: Severe malarial anemia associated with increased soluble Fas ligand (sFasL) concentrations in Gabonese children. Eur Cytokin Tset 2003, 14:238-241.
41. Aggarwal BB: Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol 2003, 3:747-756.
42. Calandra T, Bernhagen J, Mitchell RA, Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994, 179:1895-1902.
43. Lan HY, Ng SY, Metz C, Mu W, Song Q, Nilkolopaterson DJ, Bacher M, Bucala R, Atkin RC: TNF-alpha up-regulates retnal MIF expression in rat crescentic glomerulonephritis. Mol Med 1997, 3:136-144.
44. Rockett KA, Awbourn MM, Aggarwal BB, Cowden WB, Clark IA: In vivo induction of nitrate and nitrate by tumor necrosis factor, lymphomycin, and interleukin-1 – possible roles in malaria. Infect Immun 1992, 60:3725-3730.
45. Calandra T, Spiegel LA, Metz CN, Bucala R: Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by gram-positive bacteria. Proc Natl Acad Sci USA 1998, 95:11383-11388.
46. David J: Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1976, 56:77-79.
47. Bloom BR, Bennett B: Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966, 153:80-82.
48. Calandra T, Echtenacher B, Le Roy D, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000, 6:164-170.
49. Coleman RM, Bruce A, Rencricca NJ: Malaria: macrophage migration inhibitory factor (MIF). J Parasitol 1976, 62:137-138.
50. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R: MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377:68-71.
51. Calandra T, Bucala R: Macrophage migration inhibitory factor – a counter-regulator of glucocorticoid action and critical mediator of septic shock. J Inflamm 1995, 47(1-2):9-12.
52. Chaiyaroj SC, Rutta ASM, Muenthaisong K, Watkins P, Uboi MN, Looareeesuwan S: Reduced levels of transforming growth factor-beta 1, interleukin-12 and increased migration inhibitory factor are associated with severe malaria. Acta Trop 2004, 91:319-327.
53. Wang HC, Bloom O, Zhang MH, Vishnubhatat J, Ombrellino M, Che JT, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ: HMGI-C as a late mediator of endotoxin lethality in mice. Science 1999, 285:246-251.
54. Andersson U, Wang HC, Palmblad K, Averberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang MH, Yang H, Tracey KJ: High mobility group box 1 protein (HMGB-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000, 192:565-570.

55. Ulloa L, Fink MP, Tracey KJ: Ethyl pyruvate protects against lethal systemic inflammation by preventing HMGB1 release. Ann NY Acad Sci 2003, 987:319-321.

56. Mantell LL, Parrish WR, Ulloa L: HMGB1 as a therapeutic target for infectious and inflammatory disorders. Shock 2006, 25:4-11.

57. Alleva LM, Yang H, Tracey KJ, Clark IA: High mobility group box 1 (HMGB1) protein: possible amplification signal in the pathogenesis of falciparum malaria. Trans R Soc Trop Med Hyg 2005, 99:171-175.

58. Kokkola R, Li J, Sundberg E, Averberger AC, Palmblad K, Yang H, Tracey KJ, Andersson U, Harris HE: Successful treatment of colitis induced by dextran sodium sulfate and rats by targeting extracellular high mobility group box chromosomal protein A1. Arthritis Rheum 2003, 48:2052-2058.

59. Golgi C: Sull infezione malarica. Arch Sci Med (Torino) 1886, 10:109-135.

60. Dunn R: The Prevention of Malaria John Murray, London; 1911:101-104.

61. Bate C AW, Taverne J, Playfair JH: Malarial parasites induce TNF production by macrophages. Immunology 1988, 64:227-231.

62. Taverne J, Bate C AW, Playfair JH: Induction of TNF in vitro as a model for the identification of toxic malaria antigens. Lymp-hocyte Res 1989, 36:611-624.

63. Bate CA, Taverne J, Bootsma Hj, Mason RC, Skalko N, Gregoriadis G, Playfair JH: Antibodies against phosphatidylinositol and inositol monophosphate specifically inhibit tumour necrosis factor induction by malaria exoantigens. Immunology 1992, 76:3-41.

64. Schofield L, Vivas L, Hackett F, Zhang MH, Yang H, Tracey KJ: Ethyl pyruvate protects against lethal systemic inflammation by preventing HMGB1 release. Ann NY Acad Sci 2003, 987:319-321.

65. Mantell LL, Parrish WR, Ulloa L: HMGB1 as a therapeutic target for infectious and inflammatory disorders. Shock 2006, 25:4-11.

66. Alleva LM, Yang H, Tracey KJ, Clark IA: High mobility group box 1 (HMGB1) protein: possible amplification signal in the pathogenesis of falciparum malaria. Trans R Soc Trop Med Hyg 2005, 99:171-175.

67. Luxemburger C, Nosten F, Kyle DE, Chongsuphajsidhi T, White NJ: Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission. Trans R Soc Trop Med Hyg 1998, 92:45-49.

68. Bouchama A, De Vol EB: Acid-base alterations in heatstroke. Intensive Care Med 2001, 27:680-685.

69. Lee CC, Marill KA, Carter WA, Crupi RS: A current concept of trauma-induced multiorgan failure. Ann Emerg Med 2001, 38:170-176.

70. Donohue AM: Type A lactic acidosis in occupational heat exhaustion. Occup Med (Lond) 2003, 53:139-142.

71. Hussain FA, Martin MJ, Mulliken PS, Steele SR, Elliott DC: Serum lactate and base deficit as predictors of mortality and morbidity. Am J Surg 2003, 185:485-491.

72. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.

73. Parizel PM, Snoeck HW, van den Hauwe L, Boven K, Bosmans JL, Van Goethem JW, Van Marck EA, Craps P, De Schepper AM, De Broe ME: Cerebral complications of murine monoclonal CD3 antibody (OKT3): CT and MR findings. Am J Neuroradiol 1997, 18:227-231.

74. Patchell RA, White CL 3rd, Clark AW, Beschoren WE, Santos GW: Neurologic complications of bone marrow transplantation. Neurology 1985, 35:300-306.

75. Davis DG, Patchell RA: Neurologic complications of bone marrow transplantation. Neurology 1988, 38:377-387.

76. Eason JD, Pascual M, Wee S, Farrell M, Phelan J, Baskovic S, Blosch C, Mohler KM, Cosimi AB: Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Transplantation 1992, 51:624-628.

77. Jacobsohn DA, Vogelsang GB: Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 2002, 62:879-889.

78. Dinarello CA: Blocking interleukin-1 and tumor necrosis factor in disease. Eur Cytokine Netw 1997, 2:294-296.

79. Yoshinari D, Takeyoshi I, Koibuchi Y, Matsumoto K, Kawashima Y, Koyama T, Ohwada S, Morishita Y: Effects of a dual inhibitor of tumor necrosis factor-alpha and interleukin-1 on lipopolysaccharide-induced lung injury in rats: Involvement of the p38 mitogen-activated protein kinase pathway. Crit Care Med 2001, 29:628-634.

80. Knight JC, Udaloia I, Hill A, Greenwood BM, Peshu N, Marsh K, Kwiatkowski D: A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet 1999, 22:145-150.

81. Aidoo M, McElroy PD, Kolczak MS, Terlouw DJ, ter Kuile FO, Nahlen B, Lal AA, Udhayakumar V: Tumor necrosis factor-alpha promoter variant 2 (TNF2) is associated with pre-term delivery, induce nitric oxide synthase in falciparum malaria and sepsis in African children. Malar J 2003, 2:6.

82. Calandra T, Bucala R: Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol 1997, 17:77-88.

83. Dor C, Silva Santos JE, Assreuy J: Inhibition of glucocorticoid receptor binding by nitric oxide in endotoxemic rats. Crit Care Med 2004, 32:2304-2310.

84. Sproogens D, Friesen P, Kuf N, Frei E: Tumor necrosis factor: clinical trial and future directions. J Intern Med 1998, 243:247-254.

85. Cresswell ET, Kovach JS, Moeltel CG, Frytak S, Kovalik LC: A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 1988, 62:2467-2471.

86. Luxemburger C, Nosten F, Kyle DE, Chongsuphajsidhi T, White NJ: Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission. Trans R Soc Trop Med Hyg 1998, 92:45-49.

87. Bouchama A, De Vol EB: Acid-base alterations in heatstroke. Intensive Care Med 2001, 27:680-685.
98. Hotchkiss RS, Rust RS, Dence CS, Wasserman TH, Song SK, Hwang DR, Karl IE, Welch MJ: Evaluation of the role of cellular hypoxia in sepsis by a hypoxia marker [18F]fluoromisonadazole. Am J Physiol 1991, 261:H565-R972.

99. Boeksteegs P, Weidenhofer S, Kapsner T, Werdan K: Skeletal muscle partial pressure of oxygen in patients with sepsis. Crit Care Med 1994, 22:640-650.

100. Van der Meer TJ, Wang HL, Fink MP: Endotoxemia causes lethal mucosal acidosis in the absence of mucosal hypoxia in a normodynamic porcine model of septic shock. Crit Care Med 1995, 23:1217-1226.

101. Fink MP: Cytopathic hypoxia in sepsis. Acta Anaesthesiol Scand Supp 1997, 108:S1-11.

102. L’Her E, Sebert P: A global approach to energy metabolism in an experimental model of sepsis. Am J Respir Crit Care Med 2001, 164:1444-1447.

103. Fink MP: Cytopathic hypoxia. Mitochondrial dysfunction as a mechanism contributing to organ dysfunction in sepsis. Crit Care Clin 2001, 17:219-237.

104. Schweizer M, Richter C: Nitric oxide potently and reversibly deenergizes mitochondria at low oxygen tension. Biochem Biophys Res Commun 1994, 204:169-175.

105. Xue YW, Wu JG: Effects of nitric oxide and its interaction with superoxide in the suppression of cardiac muscle mitochondrial respiration. Involvement in response to hypoxia/reoxygenation. Circulation 1996, 94:2580-2586.

106. Plum F, Posner JB: Prognosis in Coma. 325–334 F.A. Davis Company, Philadelphia, 1988.

107. Clark IA, Cowden WB: The pathophysiology of falciparum malaria. Pharmacol Ther 2003, 99:221-260.

108. Kan H, Finkel MS: Inflammatory mediators and reversible myocardial dysfunction. J Cell Physiol 2003, 195:1-11.

109. Tatsuno T, Akashi K, Kikuchi Y, Hida W, Shirato D, Zedda C, Billiar T, Payen D, Aubier M: Activation of endogenous peroxynitrite mediates acute encephalopathy in Japanese children in 1994–2002. J Infect Dis 2006, 194:642-647.

110. Mohany D, Ghosh K, Nandwani SK, Shetty S, Phillips C, Rizvi S, Parmar BD: Fibrinolysis, inhibitors of blood coagulation, and monocyte derived interleukin 2 in acute malaria. Am J Hematol 1997, 54:23-29.

111. Imamura T, Sugiyama T, Cuevas LE, Makunde R, Nakamura S: Expression of tissue factor, the clotting initiator, on macrophages in Plasmodium falciparum-infected placenta cells. J Infect Dis 2002, 186:436-440.

112. Michelson AD, Wencel Drake JD, Kestin AS, Barnard MR: Platelet activation results in a redistribution of glycoprotein IV (CD36). Arterioscler Thromb 1994, 14:1193-1201.

113. Span AH, van Dam Miers MC, Mullers W, Endert J, Muller AD, Bruggers CA: The effect of virus infection on the adhesion of leucocytes or platelets to endothelial cells. Eur J Clin Invest 1991, 21:331-338.

114. Krishnamurti C, Peat RA, Cutting MA, Rodwell SW: Platelet adhesion to dengue-2 virus-infected endothelial cells. Am J Trop Med Hyg 2000, 62:264-266.

115. Rahbar A, Soderberg Nauckler C: Human cytomegalovirus infection of endothelial cells triggers platelet adhesion and aggregation. J Virol 2005, 79:2211-2220.

116. Gawaz M, Fateh Moghadam S, Pilz G, Gurland HJ, Werdan K: Platelet activation and interaction with leucocytes in patients with sepsis or multiple organ failure. Eur J Clin Invest 1995, 25:843-851.

117. Ruuswurm S, Vickers J, Meier Hellmann A, Spangenberg P, Bredie D, Reinhart K, Losche W: Platelet and leucocyte activation correlate with the severity of septic organ dysfunction. Shock 2002, 17:263-268.

118. Grau GE, Mackenzie CD, Carr RA, Redard M, Pizziolato G, Allasia C, Cataldo C, Taylor TE, Molyneux ME: Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria. J Infect Dis 2003, 187:461-466.

119. Rogerson SJ, Pollina E, Getachew A, Tadesse E, Lema VM, Molyneux ME: Placental monocyte infiltrates in response to Plasmodium falciparum malaria infection and their association with adverse pregnancy outcomes. Am J Trop Med Hyg 2003, 68:115-119.

120. Patnaik JK, Das BS, Mishra SK, Mohanty S, Satpathy SK, Mohanty D: Vascular clogging, mononuclear cell margination, and enhanced vascular permeability in the pathogenesis of human cerebral malaria. Am J Trop Med Hyg 1994, 51:642-647.

121. Rogerson SJ, Brown HC, Pollina E, Abrams ET, Tadesse E, Lema VM, Molyneux ME: Placental tumour necrosis factor alpha but not gamma interferon is associated with placental malaria and low birth weight in Malawian women. Infect Immun 2003, 71:267-270.

122. Rouhiainen A, Imai S, Rauvala H, Parkkinen J: Occurrence of amphotericin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost 2000, 84:1087-1094.

123. Wassmer SC, Coombes V, Candil FL, Julian Yague I, Grau GE: Platelets potentiate brain endothelial alterations induced by Plasmodium falciparum. Infect Immun 2006, 74:645-653.

124. Papadopoulos MC, Davies DC, Moss RF, Tighe D, Bennett ED: Pathophysiology of septic encephalopathy: A review. Crit Care Med 2000, 28:3019-3024.

125. Towfighi T, Matsuzono Y, Narita M, Morishita T: Influenza-associated acute encephalopathy in Japanese children in 1994–2002. Virus Res 2004, 103:75-78.

126. Bego MA, Khan R, Baig SM, Guizat Z, Hussain R, Smego RA: Cerebral involvement in benign tertian malaria. Am J Trop Med Hyg 2002, 67:230-232.

127. Kocher DK, Saxena V, Singh N, Kochar SK, Kumar SV, Das A: Plasmodium vivax malaria. Emerg Infect Dis 2005, 11:132-134.

128. Farni S, Lopez MJ, Pradines J, Thallamalli F, Kremers PC: Upregulation of ICAM-I by Plasmodium falciparum: In vitro and in vivo studies. J Clin Path 1994, 47:653-656.

129. Endo S, Inada K, Kasai T, Takakuwa T, Yamada Y, Koike S, Wakaba-yashi G, Niiimi M, Taniguchi S, Yoshida M: Levels of soluble adhesion molecules and cytokines in patients with septic multiple organ failure. J Inflamm 1995, 46:212-219.

130. Combes V, Taylor TE, Juliane V, Mege JL, Mwenechanaya J, Tembo M, Grau GE, Molyneux ME: Circulating endothelial microparticles in Malawian children with severe falciparum malaria complicated with coma. JAMA 2004, 291:2542-2544.
141. Freysinet JM: Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003, 1:1655-1662.
142. Marchalavas E, Bignami A, Sulle Febbri Estivo-Autumnali E, Loeschner, Romye: 1894.
143. Wolf P: The nature and significance of platelet products in human plasma. Br J Haematol 1967, 13:269-288.
144. Piguet PF, Vesin C, Da Kan C: Activation of platelet caspases by TNF and its consequences for kinetics. Cytokine 2002, 18:222-230.
145. Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG, Hack CE, Sturk A: Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000, 95:893-905.
146. Ogura H, Kawasaki T, Tanaka H, Koth T, Tanaka R, Ozeki Y, Hosot sub H, Kuwagata Y, Shimazu T, Sugimoto H: Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma 2001, 50:809-814.
147. Distler JH, Jungel A, Huber LC, Seemayer CA, Reich CF, Gay RE, Michel BA, Fontana A, Gay S, Piesksy DS, Distler O: The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Arterioscler Thromb Vasc Biol 2005, 25:2892-2897.
148. Combes V, Cellot N, Alibert M, van Eck M, Raymond C, Juhan Vague I, Chimini G: ABCa1 gene deletion protects against cerebral malaria: potential pathogenic role of microparticles in neuropathology. Am J Pathol 2005, 166:295-302.
149. Combes V, Cellot N, Falle I, Dassing WG, Grau GE: Cerebral malaria: role of microparticles and platelets in alterations of the blood-brain barrier. Int J Parasitol 2006, 35(S):541-6.
150. Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore DA: Isolation and characterization of soluble intercellular adhesion molecule-1 (ICAM-1), endothelial leukocyte adhesion molecule-1 (ELAM-1), and tumor necrosis factor receptor (55 kDa TNF-R) in patients with acute plasmodium falciparum malaria. Clin Immunol Immunopathol 1994, 71:344-348.
151. Prudhomme JG, Sherman IW, Land KM, Moses AV, Stenglein S, Nelson JA: Studies of Plasmodium falciparum cytoadherence using immortalized human brain capillary endothelial cells. Int J Parasitol 1996, 26:467-655.
152. Karunaweera ND, Carter RA, Grau GE, Mendis KN: Demonstration of anti-immune disease to Plasmodium vivax malaria in Sri Lanka using a quantitative method to assess clinical disease. Am J Trop Med Hyg 1998, 58:204-210.
153. Esmon CT: Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Best Pract Res Clin Haematol 1999, 12:343-359.
154. Lewis R, van der Poll T, ten Cate H: Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006, 32:33-39.
155. Esmon CT, Fukudome K, Mather T, Bode W, Regan LM, Stearns-Kurosawa D, Kurosawa S: Inflammation, sepsis, and coagulation. Haematologica 1999, 84:254-259.
156. Seydel KB, Milner DA, Kamiza SB, Molyneux ME, Taylor TE: Inflammation, fibrinolysis and Willebrand factor in normal human tissues. Thromb Haemost 1999, 82:1047-1052.
157. Anrather D, Millan MT, Patmehsofer A, Robson SC, Geczy C, Ritchie AJ, Bach FH, Ewenstein BM: Thrombin activates nuclear factor-kappa B and potentiates endothelial cell activation by TNF. J Biol Chem 2001, 276:21440-21445.
158. Kaplanski G, Marin V, Fabrigoule M, Boulay V, Benoliel R, Fauchet A, Ring D, Freyssinet JM: The role of annexins in the regulation of the endothelial glycocalyx. J Thromb Haemost 2003, 1:1691-1701.
159. Suguitan AL, Leke RGF, Fouad G, Zhou AN, Thuita L, Metenou S, Fogako J, Megnekou R, Taylor DW: Changes in the levels of chemokines and cytokines in the plasma of the patients with Plasmodium falciparum malaria. J Infect Dis 2003, 188:1074-1082.
160. Fiorucci S, Greenberg R, Schmukler ZS, McFadden GA, Sauerbrei E, Downie J: The interaction between Plasmodium falciparum-infected human erythrocytes and microvascular endothelial cells. J Infect Dis 2001, 183:1265-1266.
161. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Shimokawa I, Akiyama Y, Taniguchi N, Maruyama I: Thrombin suppression of fibrinolysis: expression and regulation of tissue factor pathway inhibitor and plasminogen activator inhibitor-1 in human microvascular endothelial cells. J Biol Chem 2001, 276:27780-27787.
162. Suguitan AL, Leke RGF, Fouad G, Zhou AN, Thuita L, Metenou S, Fogako J, Megnekou R, Taylor DW: Changes in the levels of chemokines and cytokines in the plasma of the patients with Plasmodium falciparum malaria. J Infect Dis 2003, 188:1074-1082.
183. Guzman NJ, Fang MZ, Tang SS, Ingelfinger JR, Garg LC: Autocrine inhibition of Na+/K+-ATPase by nitric oxide in mouse proximal tubular renal cells. J Clin Invest 1995, 95:2083-2088.

184. Wambach G, Overhoff U, Hossmann V: Sodium transport and red cell deformability. Klin Wochenschr 1985, 63 Suppl:35-37.

185. Kone BC, Higham S: Nitric oxide inhibits transcription of the Na+K+-ATPase alpha 1-subunit gene in an MTAL cell line. Am J Physiol 1999, 276:F614-F621.

186. Lee MV, Ambrus JL, DeSouza JM, White RJ, Vreeken J, White NJ: Red blood cell deformability as a predictor of anemia in severe falciparum malaria. Br Med J 1999, 329:697-698.

187. Rogers F, Dunn R, Barrett J, Merlotti G, Sheaff C, Nolan P: Alterations of capillary flow during sepsis. Circ Shock 1985, 15:105-110.

188. Hurd TC, Dasmahapatra KS, Rush BF Jr, Machiedo GW: Red blood cell deformability in human and experimental sepsis. Arch Surg 1988, 123:217-220.

189. Dondorp AM, Angus BJ, Chotivanich KT, Silamut K, Looareesuwan S, Warrell DA, Hardeman MR, Kager PA, Vreeken J, White NJ: Tumor necrosis factor-alpha as a myocardial depressant factor in in vitro-dial dysfunction of meningococcal septic shock. J Infect Dis 2006, 193:1384-1393.

190. Maciejewski JP, Selleri C, Sato T, Hu J, Keever LK, Nathan CF, Young NS: Nitric oxide suppression of human hematopoiesis in vitro – contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha. J Clin Invest 1995, 96:1085-1092.

191. Martinez JA, Sherry B, Metz CN, Espinoza M, Ferrer AS, Calandra T, Broxmeyer HE, Bucala R: Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-i infected erythrocytes: potential role in the pathogenesis of malaria anemia. J Infect Dis 2000, 182:2259-2267.

192. O'Sullivan MG, Anderson DC, Fikes JD, Bain FT, Carlson CS, Green SW, Young NS, Brown SM, Fournier EP: Characterization of a novel simian parvovirus in cynomolgus monkeys with severe anemia. A parasite model for human parvovirus B19 infection mimicking congenital dyserythropoietic anemia. J Pediatr Hematol Oncol 2004, 26:133-135.

193. Sheikha A: Dyserythropoiesis in 105 patients with visceral leishmaniasis. Lab Hematol 2004, 10:206-211.

194. Lu PL, Hsiao HH, Tsai JJ, Chen TC, Feng MC, Chen TP, Lin SF: Dengue virus-associated hemophagocytic syndrome and dyserythropoiesis. Kaohsiung J Med Sci 2005, 21:34-39.

195. Court O, Kumar A, Parrillo JE: Clinical review: Myocardial depression in sepsis and septic shock. Crit Care 2002, 6:500-508.

196. Wangensteen SL, Geissinger WT, Lovett WL, Glenn TH, Lefer AM: Relationship between splanchic blood flow and a myocardial depressant factor in endotoxin shock. Surgery 1971, 69:410-418.

197. Odeh M: Tumor necrosis factor-alpha as a myocardial depressant substance. J Intern Med 1993, 42A:2088.

198. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE: Tumor necrosis factor alpha and interleukin-1 beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996, 183:949-958.

199. Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE, McCabe C, Welsh SB, Whitney A, O’Gara P, Nadel S, Rehman MA, Harding SE, Levin ML: Role of interleukin-6 in myocardial dysfunction of meningococcal septic shock. Lancet 2004, 363:203-209.

192. May J, Lell B, Luty AJ, Meyer CG, Kremsner PG: Plasma interleukin-10: tumor necrosis factor (TNF)-alpha ratio is associated with TNF-positive variants and predicts malarial complications. J Infect Dis 2000, 182:1570-1573.
Malaria Journal 2006, 5:85
http://www.malariajournal.com/content/5/1/85

225. Chagnon F, Metz CN, Bucale R, Lesur O: Endotoxin-induced myocardial dysfunction – Effects of macrophage migration inhibitory factor neutralization. Circ Res 2005, 96:1095-1102.

226. Lin XC, Sakuragi T, Metz CN, Qijia K, Skopicki HA, Wang P, Ali-Abed Y, Miller EJ: Macrophage migration inhibitory factor within the alveolar spaces induces changes in the heart during late experimental sepsis. Shock 2005, 24:536-563.

227. Ehrhardt S, Wichmann D, Hammer CJ, Burchard GD, Bratza NW: Circulating concentrations of cardiac proteins in complicated and uncomplicated Plasmodium falciparum malaria. Trop Med Int Health 2004, 9:1099-1103.

228. Ehrhardt S, Mockenhaupt FP, Anemana SD, Ochowemah RN, Wichmann D, Cramer JP, Bierle U, Burchard GD, Bratza NW: High levels of circulating cardiac proteins indicate cardiac impairment in African children with severe Plasmodium falciparum malaria. Microbes Infect 2005, 7:1204-1210.

229. Ince C: The microcirculation is the motor of sepsis. Crit Care Med 2006, 34:587-595.

230. Kean BH, Taylor CE: Medical shock in the pathogenesis of algid amnesia. Am J Trop Med Hyg 1946, 26:209-219.

231. Maitland K, Levin M, Mithwani S, Peshu N, Marsh K, Newcomer CN: Severe P. falciparum malaria in Kenyan children: evidence for hypoxia-1alpha. J Infect Dis 2003, 96:427-433.

232. English M, Waruiru C, Marsh K: Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. Clin Infect Dis 2005, 40:538-545.

233. Planche T, Ongana A, Schwenk A, Dzein A, Bornmann S, Sauber JC, Wright A, Bluck L, Ward L, Kombila M, Krensger P, Krishna S: Assessment of volume depletion in children with malaria. PLoS Med 2004, 1:e18.

234. Maitland K, Pamba A, English M, Peshu N, Marsh K, Newcomer CN, Levin M: Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. Clin Infect Dis 2005, 40:538-545.

235. Planche T, Ongana A, Schwenk A, Dzein A, Bornmann S, Sauber JC, Wright A, Bluck L, Ward L, Kombila M, Krensger P, Krishna S: Assessment of volume depletion in children with malaria. PLoS Med 2004, 1:e18.

236. Maitland K, Newton CR: Acidosis of severe falciparum malaria: heading for a shock? Trends Parasitol 2005, 21:11-16.

237. Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, Marsh V, Newton C, Waruiru P, Warn P, Peulv P, Pasrol G, Snow R: Indicators of life-threatening malaria in African children. N Engl J Med 1995, 332:1399-1404.

238. Carillo JA, Tasker RC: Fluid resuscitation of hypovolemic shock: acute medicine's great triumph for children. Intensive Care Med 2006, 32:958-961.

239. Planche T, Krishna S: The relevance of malaria pathophysiology to strategies of clinical management. Curr Opin Infect Dis 2005, 18:369-375.

240. Kreisberg RA: Lactate homeostasis and lactic acidosis. Ann Intern Med 1980, 92:227-237.

241. Ayachoura JE, Wong HB, Quah SK, Jacob E, Chio LF, Sothy SP: The significance of type B hyperlactataemia in infective encephalopathy. Ann Acad Med Singapore 1987, 16:73-77.

242. Dekker E, Hellekens MK, Romijn JA, Neese RA, Peshu N, Endert E, Marsh K, Sauerwein HP: Glucose homeostasis in children with falciparum malaria: precursor supply limits gluconeogenesis and glucose production. J Clin Endocrinol Metab 1997, 82:2514-2521.

243. McCann SJ, Wallace RJ, Muster DM, Septimus EJ, Kohl S, Baughn RE: Hypoglycaemia as a manifestation of sepsis. Am J Med 1980, 68:649-654.

244. Phillips RE: Hypoglycaemia is an important complication of falciparum malaria. Quart J Med 1989, 71:477-483.

245. White NJ, Warrell DA, Chanthavanich P, Looareesuwan S, Warrell MJ, Krishna S, Williamon DH, Turner RC: Severe hypoglycaemia and hypoglycaemia in falciparum malaria. N Engl J Med 1983, 309:61-66.

246. Taylor TE, Borgstein A, Molyneux ME: Acid-base status in paediatric Plasmodium falciparum malaria. Quart J Med 1993, 86:99-109.

247. Levy B, Sadowsa LO, Geltom AT, Bolleart PF, Nabet P, Larcun A: Evolution of lactate/pyruvate and arterial ketone body ratios in the early course of severe Plasmodium-tREATED septic shock. Crit Care Med 2000, 28:114-119.

248. ter Hofstede HJ, Willems HL, Koopmans PP: Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers. J Clin Virol 2004, 29:44-50.

249. Day NP, Phu NH, Mai NT, Chau TT, Loc PP, Chuong LV, Sinh DX, Holloway P, Hien TT, White NJ: The pathophysiological and prognostic significance of acidosis in severe adult malaria. Crit Care Med 2000, 28:1833-1840.

250. Clark IA, Awburn MM, Harper CG, Liomba NG, Molyneux ME: Induction of HO-1 in tissue macrophages and monocytes in fatal falciparum malaria and sepsis. Mal J 2003, 2:41.

251. Krebs HA, Woods HF, Alberti KG: Hyperlactataemia and lactic acidosis. Essays Med Biochem 1975, 1:81-103.

252. Clark IA, Awburn MM, Harper CG, Liomba NG, Molyneux ME: Induction of HO-1 in tissue macrophages and monocytes in fatal falciparum malaria and sepsis. Malar J 2003, 2:41.

253. Lauterbach R, Zembala M: Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis. Eur J Perinatol 1996, 15:504-509.

254. Brealey D, Brand M, Hardie JS, Land J, Smolenski R, Singer M: Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002, 360:219-223.

255. Brealey D, Karyampudi S, Jacques TS, Novelli M, Sidwell R, Taylor V, Smolenski RT, Singer M: Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure. Am J Physiol Regul Integr Comp Physiol 2004, 286:R491-497.

256. Crouser ED: Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion 2004, 4:729-741.

257. Maegraith B, Fletcher A: The pathogenesis of mammalian malaria. Adv Parasitol 1972, 10:49-73.

258. Riley MV, Maegraith BG: A factor in the serum of malaria-infected animals capable of inhibiting the in vitro oxidative metabolism of normal liver mitochondria. Am Trop Med Parasitol 1961, 55:489-497.

259. Thurnham DI, Fletcher KA, Maegraith BG: The inhibition of mitochondrial respiration and oxidative phosphorylation by serum from malaria-infected animals. II. The inhibitory activity of serum ultrafractates from Plasmodium knowlesi-infected monkeys. Am Trop Med Parasitol 1971, 65:287-295.

260. Maegraith BG: Physiological aspects of protozoan infection. Ann Rev Microbiol 1954, 8:273-288.

261. Sandeau KB, Zhou J, Kietzmann T, Brun E: Regulation of the hypoxia-inducible factor-1 alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferoxamine and phenylarsine oxide. J Biol Chem 2001, 276:39805-39811.

262. Gleaves JM, Ratcliffe PJ: Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Sre kinase. Blood 1997, 89:503-509.

263. Bell EL,Emerling BR, Chander NS: Mitochondrial regulation of oxygen sensing. Mitochondrion 2005, 5:322-332.

264. Cerra FB: Hypermetabolism, organ failure, and metabolic support. Surgery 1987, 101:1-14.

265. Gore DC, Jahoor F, Hibbert JM, Demaria EJ: Lactic acidosis during sepsis is related to increased pyruvate production, not deficits in tissue oxygen availability. Ann Surg 1996, 224:97-102.

266. Hellwig-Burgel T, Stiehl DP, Wagner AE, Metzen E, Jellman W: Hypoxia-inducible factor-1 (HIF-1): A novel transcription factor in immune reactions. J Interferon Cytokine Res 2005, 25:297-310.
271. Clark I, Awbourn M: Migration inhibitory factor in the cerebral and systemic endothelium in sepsis and malaria. Crit Care Med 2002, 30:253-267.

272. Benigni F, Azumi T, Calandra T, Metz C, Echtenacher B, Peng T, Bucala R: The proinflammatory mediator macrophage migration inhibition factor induces glucose catabolism in muscle. J Clin Invest 2000, 106:1291-1300.

273. Koong AC, Denko NC, Hudson TM, Schindler C, Swiercz L, Koch C, Evans S, Ibrahim H, Le QT, Terris DJ, Giaccia AJ: Candidate genes for the hypoxic tumor phenotype. Cancer Res 2000, 60:883-891.

274. Levraut J, Grimaud D: Treatment of metabolic acidosis. Curr Opin Crit Care 2003, 9:260-265.

275. Krishna S, Agbenyega T, Angus BJ, Beduaddo G, Oforiamanfo G, Adusei K: Shock and cardiogenic shock. Acta Trop 1993, 51:15-20.

276. Krishna S, Supanaranond W, Pukrittayakamee S, Karter D, Supputthammatikul S: Malaria – indicator of metabolic acidosis and poor outcome. J Med Assoc Thai 2004, 87:S5.

277. Krishna S, Agbenyega T, Angus BJ, Beduaddo G, Oforiamanfo G, Adusei K: Shock and cardiogenic shock. Acta Trop 1993, 51:15-20.

278. Deshpande SA, Platt MP: Association between blood lactate and acid-base status and mortality in ventilated babies. Arch Dis Child Fetal Neonatal Ed 1997, 76:F1-F20.

279. Gutierrez G, Wulf ME: Lactic acidosis in severe malaria: a pharmacokinetic and pharmacodynamic assessment. Metabolism 1994, 43:974-981.

280. Deshpande SA, Platt MP: Association between blood lactate and acid-base status and mortality in ventilated babies. Arch Dis Child Fetal Neonatal Ed 1997, 76:F1-F20.

281. Schurr A, Payne RS, Miller JJ, Rigor BM: Induction of diaphragmatic nitric oxide synthase during endotoxin administration in rats – role in diaphragmatic contractile dysfunction. J Clin Invest 1996, 98:1550-1559.

282. Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Mecher C, Rackow EC, Astiz ME, Weil MH: Downregulation of diaphragm electron transport chain and glycolytic enzyme gene expression in sepsis. Free Radic Biol Med 2006, 40:127-137.

283. Genton B, Aiyaman F, Alpers MP, Mokela D: Indicators of fatal outcome in paediatric cerebral malaria: a study of 134 compared fatal cases of paediatric cerebral malaria in Papua New Guinea Children. Int J Epidemiol 1997, 26:670-676.

284. Cannon PR: Some pathological aspects of human malaria I-214-220 American Association for the Advancement of Science, Washington; 1941.

285. Revelly JP, Tappy L, Martinez A, Bollmann M, Cayeux MC, Berger MM: Malaria: Host-parasite interaction and morbidity in malaria endemic areas. Philos Trans R Soc Lond B Biol Sci 1997, 352:1385-1394.

286. Rosner F, Zarrabi MH, Benach JL, Habicht GS: Babesiosis in splenectomized adults. Review of 22 reported cases. Am J Med 1993, 94:767-701.

287. Shaw MF, Lin PR: A case study of cytokine profiles in acute human babesiosis. Am J Trop Med Hyg 1998, 58:335-337.

288. Molloy JB, Bowles PM, Jorgensen WK, Cooke BM: Babesiosis: adhesion of parasitized red blood cells to bovine umbilical vein endothelial cells in vitro does not select for virulence. Exp Parasitol 2003, 101:182-184.

289. English M, Bergerly J, Lowe B, Shebe M, Mkwakesi R, Kokwaro GM: Characterization of metabolic acidosis in Kenyan children admitted to hospital for acute non-surgical conditions. Trans R Soc Trop Med Hyg 2006, 100:401-409.

290. Koong AC, Denko NC, Hudson TM, Schindler C, Swiercz L, Koch C, Evans S, Ibrahim H, Le QT, Terris DJ, Giaccia AJ: Candidate genes for the hypoxic tumor phenotype. Cancer Res 2000, 60:883-891.

291. Boczkowski J, Lanone S, Ungureanu-Falas u D, Danielou G, Fournier T, Aubier M: Malaria – indicator of metabolic acidosis and poor outcome. J Med Assoc Thai 2004, 87:S5.

292. Boczkowski J, Lanone S, Ungureanu-Falas u D, Danielou G, Fournier T, Aubier M: Malaria – indicator of metabolic acidosis and poor outcome. J Med Assoc Thai 2004, 87:S5.

293. Trencher DS, Davies N, Brealey D, Singer M, Cooper CE: Mitochondrial dysfunction in patients with severe sepsis: an EPR interrogation of respiratory chain components. Biochim Biophys Acta 2006, 1757:262-272.

294. Callahan LA, Supinski GS: Sepsis induces diaphragm electron transport chain dysfunction and protein depletion. Am J Resp Crit Care Med 2005, 172:S61-686.

295. Callahan LA, Supinski GS: Downregulation of diaphragm electron transport chain and glycolytic enzyme gene expression in sepsis. J Appl Physiol 2005, 99:1120-1126.

296. Clanahan LA, Callahan LA: Hemin prevents cardiac and diaphragm mitochondrial dysfunction in sepsis. Free Radic Biol Med 2006, 40:127-137.

297. Kosinski GA, Davies N, Brealey D, Singer M, Cooper CE: Mitochondrial dysfunction in patients with severe sepsis: an EPR interrogation of respiratory chain components. Biochim Biophys Acta 2006, 1757:262-272.

298. Callahan LA, Supinski GS: Sepsis induces diaphragm electron transport chain dysfunction and protein depletion. Am J Resp Crit Care Med 2005, 172:S61-686.

299. Callahan LA, Supinski GS: Downregulation of diaphragm electron transport chain and glycolytic enzyme gene expression in sepsis. J Appl Physiol 2005, 99:1120-1126.

300. Supinski GS, Callahan LA: Hemin prevents cardiac and diaphragm mitochondrial dysfunction in sepsis. Free Radic Biol Med 2006, 40:127-137.

301. Hanke RV, Smith JA: Death due to estivo-autumnal malaria: A resume of one hundred autopsy cases, 1925-1942. Am J Med 1944, 16:214-220.

302. Donnord AM, Pongonnatt E, White NJ: Reduced microcirculatory flow in severe falciparum malaria: pathophysiology and electron-microscopic pathology. Acta Trop 2004, 89:309-317.

303. Wilson DB, Garnham PCC, Szwandt ISF, Obrien R, Stacpoole PW: Characterisation of metabolic acidosis in Kenyan children admitted to hospital for acute non-surgical conditions. Trans R Soc Trop Med Hyg 2006, 100:401-409.

304. Shah MF, Lin PR: A case study of cytokine profiles in acute human babesiosis. Am J Trop Med Hyg 1998, 58:335-337.

305. Molloy JB, Bowles PM, Jorgensen WK, Cooke BM: Babesiosis: adhesion of parasitized red blood cells to bovine umbilical vein endothelial cells in vitro does not select for virulence. Exp Parasitol 2003, 101:182-184.

306. English M, Bergerly J, Lowe B, Shebe M, Mkwakesi R, Kokwaro GM: Characterization of metabolic acidosis in Kenyan children admitted to hospital for acute non-surgical conditions. Trans R Soc Trop Med Hyg 2006, 100:401-409.

307. Clark IA, Budd AC, Hsue H, Haymore BR, Joyce AJ, Thorner R, Molyneux M: The role of KAHRP domains in knob formation and cytoadhesion. Trop Dis Bull 2004, 97:147-153.

308. Rowin KS, Tanowitz HB, Rubinstein A, Kunkel M, Wirtzmann M: Babesiosis in asplenic hosts. Trans R Soc Trop Med Hyg 1984, 78:442-444.

309. Rosner F, Zarrabi MH, Benach JL, Habicht GS: Babesiosis in splenectomized adults. Review of 22 reported cases. Am J Med 1993, 94:767-701.

310. Shaw MF, Lin PR: A case study of cytokine profiles in acute human babesiosis. Am J Trop Med Hyg 1998, 58:335-337.

311. Molloy JB, Bowles PM, Jorgensen WK, Cooke BM: Babesiosis: adhesion of parasitized red blood cells to bovine umbilical vein endothelial cells in vitro does not select for virulence. Exp Parasitol 2003, 101:182-184.

312. English M, Sauerwein R, Waruiru C, Mosobu M, Obiero J, Lowe B, Marsh K: Acidosis in severe childhood malaria. Q J Med 1997, 90:263-270.

313. Taylor C, Carr R, NG L, Whitten R, Dzamalala C, Molyneux M: The diverse pathologies of fatal cerebral malaria. Abstracts for the 3rd MIM Pan-African Conference on Malaria, Arusha, Tanzania, November 18 – 22, 2002 2000.

314. Marsh K, English M, Crawley J, Peshu N: The pathogenesis of severe malaria in African children. Ann Trop Med Parasitol 1996, 90:395-402.

315. Rogerson SJ, Grau GE, Hunt NH: The microcirculation in severe malaria. Microcirculation 2004, 11:559-576.

316. Clark IA, Chaudhri G, Cowden WB, Cowden WD: Roles of tumour necrosis factor in the illness and pathology of malaria. Trans R Soc Trop Med Hyg 1989, 83:436-440.
ence of *P. falciparum* -infected human erythrocytes. Blood 2006, 108:370-378. DOI 10.1182/blood-2005-1111-1462.

31. Vanrell DA, Schell N, Chanthavichai K, Karbwang J, White NJ, Looareesuwan S, Phillips RE, Pongpawee P. Cerebral anaerobic glycolysis and reduced cerebral oxygen transport in human malaria. Lancet 1988, 8(610):534-538.

32. Clairv N, Rahimi C, Falanga P, Ayivi B, Payen D. No evidence for cerebral hypoperfusion during cerebral malaria. Crit Care Med 1999, 27:628-632.

33. Newbold C, Warn P, Black G, Berendt A, Craig A, Snow B, Msombo M, Peshu N, Marsh K. Receptor-specific adhesion and clinical disease in plasmodium falciparum. Am J Trop Med Hyg 1997, 57:389-396.

34. Rogerson SJ, Tjemburo R, Dobano C, Platt S, Taylor TE, Molyneux ME. Cytoadherence characteristics of *Plasmodium falciparum* -infected erythrocytes from Malawian children with severe and uncomplicated malaria. Am J Trop Med Hyg 1999, 61:450-452.

35. Yipp BG, Baruch DI, Brady C, Murray AG, Looareesuwan S, Kubes P, Anstey NM, Jacups SP, Cain T, Pearson T, Ziesing PJ, Fisher DA, Sprung CL, Peduzzi PN, Shatney CH, Schein RM, Wilson MF, Shea-Perel E, Morita H, Hosoya M, Kato A, Kawasaki Y, Suzuki H: Apoptosis and microglial activation in influenza encephalopathy and disease mechanisms. Clin Chim Acta 2003, 342:215-226.

36. van Zeijl JH, Bakkers J, Wilbrink B, Melchers WJG, Mullaart RA, Yang YL, Li JP, Li KZ, Dou KF: Recombinant PfEMP1 peptide inhibits and reverses cytoadherence of *Plasmodium falciparum* isolates in vivo. Blood 2003, 101:331-337.

37. Togashi T, Takashima S: Cerebral microthrombosis -a potential prognostic indicator in patients with systemic inflammatory response syndrome. Clin Chim Acta 2004, 342:127-136.

38. Hosoya M, Kawasaki Y, Katayose M, Sakuma H, Watanabe M, Igarashi E, Aoyama M, Nunoi H, Suzuki H. Prognostic predictive values of serum cytotoxanthin c, cytokines, and other laboratory measurements in acute encephalopathy with multiple organ failure. Arch Dis Child 2006, 91:469-472.

39. Mabry CC. Phenylketonuria: contemporary screening and diagnosis. Ann Clin Lab Sci 1990, 20:393-397.

40. Hohyla M, Sprong L, Tichy M, Pedra M: Leucine metabolism in rat liver after a bolus infection of endotoxin. Metabolism 1998, 47:681-685.

41. Carbo N, Lopez Soriano FJ, Argiles JM: The effects of tumour necrosis factor-alpha on circulating amino acids in the pregnant rat. Cancer Lett 1994, 79:27-32.

42. Takekawa J, Taenaka N, Nishijima MK, Hirata T, Okada T, Shimada Y, Yoshiya I: Amino acids and thiobarbituric acid reactive substances in cerebrospinal fluid and plasma of patients with septic encephalopathy. Crit Care Med 1983, 11:876-879.

43. Yipp BG, Schilling SA, Looareesuwan S, Peck SE, Kubota K, Phillips RE, Pongpaew P: Septic encephalopathy. Diagnosis and therapy. Anesth Analges 2003, 52:294-303.

44. Enwonwu CO, Afolabi BM, Salako LA, Idsegue EO, Al Hassan H, Rabiu RA: Hyperphenylalaninaemia in children with falciparum malaria. Q J Med 1999, 92:495-503.

45. Logue AS, Anstey NM, Stoddard GJ, Mwaikambo ED, Boutis CS, Tillett E, Manihoey B, Hobbbs MR, Levesque MC, Weinberg JB, Granger DL: Elevated plasma phenylalanine in severe malaria and implications for pathophysiology of neurological complications. Infect Immun 2006, 74:3335-3339.

46. Hervez MP, Lackner A: Metabolized cerebrospinal fluid quinolinic acid, kynurenic acid, and L-kynurenine in acute septicemia. J Neurol 1990, 55:338-341.

47. Pellegrin K, Neurauter G, Wirleitner B, Fleming AW, Peterson VM, Fuchs D: Enhanced enzymatic degradation of tryptophan by indoleamine 2,3-dioxygenase contributes to the tryptophan-deficient state seen after major trauma. Shock 2005, 23:209-215.

48. Clark IA, Cowden WB: Roles of TNF in malaria and other parasitic infections. In *Tumor Necrosis Factors; Structures, Functions and Mechanisms of Action* Edited by: Aggarwal BB, Vilcek J. Marcel Dekker, New York; 1991:365-407.

49. Arii J, Tanabe Y, Miyake M, Mukai T, Matsuzaki M, Niinomi N, Watanabe H, Yokota Y, Kohno Y, Noda M: Clinical and pathologic characteristics of nontyphoidal salmonella encephalopathy. Neurology 2002, 58:1641-1645.

50. Stocchetti N: Brain and sepsis: functional impairment, structural damage, and markers. Anesth Analg 2005, 101:1463-1464.

51. Medana IM, Lindert RB, Wurster U, Hien TT, Day NPJ, Phu NH, Mai NTH, Van Chung L, Chau TTH, Turner GDH, Farrar JJ, White NJ: Cerebral microthrombosis levels of markers of brain parenchymal damage in Vietnamese adults with severe malaria. Trans R Soc Trop Med Hyg 2005, 99:610-617.

52. Gunduz Z, Yavuz I, Koparal M, Kandemars S, Saraymen R: Serum and cerebrospinal fluid zinc levels in children with febrile convulsions. Acta Paediatr Jpn 1996, 38:237-241.

53. Baudier J, Glasser N, Gerard D: Ions binding to S100 proteins. I. Calcium- and zinc-binding properties of bovine brain S100 alpha, alpha, S100 beta, beta, and S100b (beta beta) proteins. *J Biol Chem* 1986, 261:8192-8203.

54. DellAngelica EC, Schleicher CH, Santome JA: Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes. *J Biol Chem* 1994, 269:28929-28936.

55. Takeda A: Zinc homeostasis and functions of zinc in the brain. *Biometals* 2001, 14:343-351.

56. Xie XM, Smart TG: A physiological role for endogenous zinc in rat hippocampal synaptic neurotransmission. *Nature* 1991, 349:521-524.

57. Ghia HA, ElGhazali G, TM A-E, IE A-E, Eltahir EM, Baraka OZ, Khier MM, Adam I, Troye-Blomberg M, Theander TG, Elbashir MI: Hyperphenylalaninaemia in children with falciparum malaria. Q J Med 1999, 92:495-503.

58. Logue AS, Anstey NM, Stoddard GJ, Mwaikambo ED, Boutis CS, Tillett E, Manihoey B, Hobbbs MR, Levesque MC, Weinberg JB, Granger DL: Elevated plasma phenylalanine in severe malaria and implications for pathophysiology of neurological complications. *Infect Immun* 2006, 74:3335-3339.

59. Hervez MP, Lackner A: Metabolized cerebrospinal fluid quinolinic acid, kynurenic acid, and L-kynurenine in acute septicemia. *J Neurol* 1990, 55:338-341.

60. Pellegrin K, Neurauter G, Wirleitner B, Fleming AW, Peterson VM, Fuchs D: Enhanced enzymatic degradation of tryptophan by indoleamine 2,3-dioxygenase contributes to the tryptophan-deficient state seen after major trauma. *Shock* 2005, 23:209-215.

61. Clark IA, Cowden WB: Roles of TNF in malaria and other parasitic infections. In *Tumor Necrosis Factors; Structures, Functions and Mechanisms of Action* Edited by: Aggarwal BB, Vilcek J. Marcel Dekker, New York; 1991:365-407.

62. Arii J, Tanabe Y, Miyake M, Mukai T, Matsuzaki M, Niinomi N, Watanabe H, Yokota Y, Kohno Y, Noda M: Clinical and pathologic characteristics of nontyphoidal salmonella encephalopathy. *Neurology* 2002, 58:1641-1645.
359. Tsukahara H, Hiraoka M, Hori C, Miyahmoe T, Kikuchi K, Sudo M: Age-related changes of urinary nitrite/nitrate excretion in normal children. Nephron 1997, 76:307-309.

360. Anstey NM, Weinberg JB, Wang ZQ, Mwaikambo ED, Duffy PE, Granger DL: Effects of age and parasitemia on nitric oxide production/leukocyte nitric oxide synthase type 2 expression in asymptomatic, malaria-exposed children. Am J Trop Med Hyg 1999, 61:253-258.

361. Calkins CM, Bensard DD, Moore EE, McIntyre RC, Silliman CC, Biffi W, Harken AH, Partrick DA, Offner PJ: The injured child is resistant to multiple organ failure: a different inflammatory response? J Trauma 2002, 53:1058-1063.

362. Barsness KA, Bensard DD, Partrick DA, Calkins CM, Hendrickson RJ, McIntyre RC: Endotoxin induces an exaggerated interleukin-10 response in peritoneal macrophages of children compared with adults. J Pediatr Surg 2004, 39:912-915.

363. Barsness KA, Bensard DD, Partrick DA, Calkins CM, Hendrickson RJ, Banerjee A, McIntyre RC: IL-1 beta induces an exaggerated pro- and anti-inflammatory response in peritoneal macrophages of children compared with adults. Pediatr Surg Int 2004, 20:238-242.